10/ 071,032

```
Welcome to STN International!  Enter x:
x
Welcome to STN International!  Enter x:
LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:27:29 ON 14 JAN 2004

=> file reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

10/ 071,032

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:28:14 ON 14 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JAN 2004 HIGHEST RN 636984-67-3
DICTIONARY FILE UPDATES: 12 JAN 2004 HIGHEST RN 636984-67-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading 10071032.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 SO2,O,S,N,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 13:28:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5414 TO ITERATE

100.0% PROCESSED 5414 ITERATIONS 593 ANSWERS
SEARCH TIME: 00.00.01

L2 593 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       155.84     156.05

FILE 'CAPLUS' ENTERED AT 13:29:20 ON 14 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Jan 2004  VOL 140 ISS 3
FILE LAST UPDATED: 13 Jan 2004  (20040113/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3          45 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 45 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 45  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:        2003:201542  CAPLUS
DOCUMENT NUMBER:         138:217443
TITLE:                   Rapid identification and classification of
                         metalloenzyme inhibitors using ligands to the
                         functional metal cation
INVENTOR(S):             Dyer, Richard Dennis; Hupe, Donald John; Johnson, Adam
                         Richard
PATENT ASSIGNEE(S):      Warner-Lambert Company, USA
SOURCE:                  Eur. Pat. Appl., 17 pp.
                         CODEN: EPXXDW
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     EP 1291439         A2   20030312       EP 2002-255715   20020815
     EP 1291439         A3   20031119
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     US 2003129672      A1   20030710       US 2002-206479   20020726
     JP 2003079394      A2   20030318       JP 2002-251608   20020829
PRIORITY APPLN. INFO.:                   US 2001-315594P  A  20010829
AB   The present invention is a method for identifying a compd. as a
     competitive, noncompetitive, or uncompetitive inhibitor of an enzyme
     having a functional metal cation.  The method comprises assaying the
```

compd. for inhibition of the enzyme in the presence of a ligand to the functional metal cation. The ratio (IC50 of the inhibitor with the metalloenzyme in the presence of ligand) divided by (IC50 of the compd. with the metalloenzyme in the presence of ligand) is less than 1 for noncompetitive or uncompetitive inhibitors; if the ratio is equal to 1, the inhibitor is noncompetitive, and if the ratio is >1, the inhibitor is competitive. Thus, synergistic inhibition of matrix metalloproteinases MMP-2, MMP-9, and MMP-13 by noncompetitive inhibitor N-[(3-phenylisoxazol-4-ylmethyl)aminothiocarbonyl]benzamide gave IC50 ratios of 0.1, 0.39, and 0.09, resp., in the presence or absence of acetohydroxamic acid as ligand. The method provides rapid and easy identification of competitive, noncompetitive, or uncompetitive inhibitors of a metalloenzyme, and avoids laborious and time-consuming enzyme kinetics expts.

IT **449799-04-6**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metalloproteinases inhibition by; rapid identification and classification of metalloenzyme inhibitors using ligands to the functional metal cation)

RN 449799-04-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:117831 CAPLUS
DOCUMENT NUMBER: 138:170250
TITLE: Oxazolo[3,2-c]pyrimidine-5,7-dione derivatives and their analogs, active as gonadotropin-releasing hormone receptor antagonists, and their pharmaceutical compositions and methods of use
INVENTOR(S): Pontillo, Joseph; Chen, Chen
PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011870	A1	20030213	WO 2002-US24493	20020802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003109535	A1	20030612	US 2002-211993	20020802

10/ 071,032

PRIORITY APPLN. INFO.: US 2001-309980P P 20010802
OTHER SOURCE(S): MARPAT 138:170250
GI



I II

AB GnRH receptor antagonists are disclosed, which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. Also disclosed are compns. contg. a compd. of the invention, in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof. Specifically, title compds. I are claimed [wherein: A = O, S, OCR7R8, or NR7; n = 2, 3 or 4; R1, R2 = H, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, C(R8)(:NR9) or C(NR10R11)(:NR9); or NR1R2 = (un)substituted heterocycle; R3a and R3b = H, alkoxy, alkylthio, alkylamino, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, COOR12 or CONR10R11; or CR3aR3b = (un)substituted homocycle or heterocycle; or R1NCR3a = (un)substituted heterocycle; R4 = (un)substituted aryl, arylalkyl, heteroaryl, or heteroarylalkyl; R5 = H, (un)substituted alkyl; R6 = (un)substituted aryl or heteroaryl; R7 = H, (un)substituted alkyl; R8 = H, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; R9 = H, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, heterocyclealkyl; R10, R11 = H, (un)substituted alkyl, aryl, arylalkyl, heterocyclyl, or heterocyclylalkyl; and R12 = H, alkyl, or substituted alkyl]. Also claimed are stereoisomers, prodrugs, and pharmaceutically acceptable salts of I. Four synthetic examples are given. For instance, N-(2-hydroxy-1-phenylethyl)-2-(2-fluorophenyl)acetamide (prepn. given) was treated with SOCl2 and then aq. NaHCO3 and NaOH to give 2-(2-fluorobenzyl)-4-phenyl-2-oxazoline. Cyclization of this with chlorocarbonyl isocyanate gave a pyrimidinedione deriv., which underwent Mitsunobu reaction with N-Boc-D-phenylglycinol at nitrogen, followed by deprotection using TFA, to give title compd. II. In a GnRH receptor membrane binding assay, compds. I had Ki of 100 .mu.M or less (no addnl. data).

IT **496927-21-0P**, 6-((2R)-2-Amino-2-phenylethyl)-8-(2-fluorophenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-22-1P**, 6-((2R)-2-Amino-2-phenylethyl)-8-(2-fluoro-3-methoxyphenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-23-2P**, 6-((2R)-2-Amino-2-phenylethyl)-8-(2-chlorophenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-24-3P**, 6-((2R)-2-Amino-2-phenylethyl)-8-(2-chlorophenyl)-3-phenyl-2,3-dihydrothiazolo[3,2-c]pyrimidine-5,7-dione **496927-25-4P**, 6-((2R)-2-Amino-2-phenylethyl)-8-(2-fluorophenyl)-3-(S)-phenyl-2,3-dihydrothiazolo[3,2-c]pyrimidine-5,7-dione **496927-38-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of oxazolopyrimidinedione derivs. and analogs as gonadotropin-releasing hormone receptor antagonists)

RN 496927-21-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-fluorophenyl)-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-22-1 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-fluoro-3-methoxyphenyl)-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-23-2 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-chlorophenyl)-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-24-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-chlorophenyl)-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-25-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-fluorophenyl)-2,3-dihydro-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-38-9 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(2R)-2-amino-2-phenylethyl]-8-(2-chlorophenyl)-2,3-dihydro-3-phenyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10/ 071,032

CM 1

CRN 496927-23-2
CMF C26 H22 Cl N3 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **496927-28-7P**, 8-(2-Fluorophenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-(6H)-dione **496927-29-8P**, 6-((2R)-((tert-Butoxycarbonyl)amino)-2-phenylethyl)-8-(2-fluorophenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-30-1P**, 3-Phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-(6H)-dione **496927-31-2P**, 8-Bromo-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-(6H)-dione **496927-32-3P**, 8-Bromo-6-((2R)-((tert-butoxycarbonyl)amino)-2-phenylethyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-33-4P**, 6-[(2R)-((tert-Butoxycarbonyl)amino)-2-phenylethyl)-8-(2-chlorophenyl)-3-phenyl-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **496927-36-7P**, 8-(2-Chlorophenyl)-3-(2-fluorophenyl)-2,3-dihydrothiazolo[3,2-c]pyrimidine-5,7-(6H)-dione
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of oxazolopyrimidinedione derivs. and analogs as gonadotropin-releasing hormone receptor antagonists)

RN 496927-28-7 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(2-fluorophenyl)-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)



RN 496927-29-8 CAPLUS
CN Carbamic acid, [(1R)-2-[8-(2-fluorophenyl)-2,3-dihydro-5,7-dioxo-3-phenyl-5H-oxazolo[3,2-c]pyrimidin-6(7H)-yl]-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-30-1 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)



RN 496927-31-2 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-bromo-2,3-dihydro-3-phenyl- (9CI) (CA INDEX NAME)



10/ 071,032

RN 496927-32-3 CAPLUS
CN Carbamic acid, [(1R)-2-(8-bromo-2,3-dihydro-5,7-dioxo-3-phenyl-5H-oxazolo[3,2-c]pyrimidin-6(7H)-yl)-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-33-4 CAPLUS
CN Carbamic acid, [(1R)-2-[8-(2-chlorophenyl)-2,3-dihydro-5,7-dioxo-3-phenyl-5H-oxazolo[3,2-c]pyrimidin-6(7H)-yl]-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 496927-36-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(2-chlorophenyl)-3-(2-fluorophenyl)-2,3-dihydro- (9CI) (CA INDEX NAME)



IT **496927-37-8**, 8-(2-Fluorophenyl)-3-(S)-phenyl-2,3-dihydrothiazolo[3,2-c]pyrimidine-5,7-dione
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of oxazolopyrimidinedione derivs. and analogs as gonadotropin-releasing hormone receptor antagonists)
RN 496927-37-8 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(2-fluorophenyl)-2,3-dihydro-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:953205 CAPLUS
DOCUMENT NUMBER: 138:385381
TITLE: Versatile, convenient synthesis of pyrimido[1,2,3-cd]purinediones
AUTHOR(S): Weyler, Stefanie; Hayallah, Alaa M.; Muller, Christa E.
CORPORATE SOURCE: Pharmazeutische Chemie Poppelsdorf, Pharmazeutisches Institut, Universitat Bonn, Bonn, D-53115, Germany
SOURCE: Tetrahedron (2002), Volume Date 2003, 59(1), 47-54
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:385381

AB The alkylation of 3-substituted cycloalkylcarboxamido-6-aminouracil derivs. with 3-bromo-1-propanol followed by ring closure yields 1,3,8-trisubstituted xanthine derivs. bearing a polar hydroxyl group. Use of the more reactive 1,3-dibromopropane or homologous dibromoalkanes for the alkylation reaction results in simultaneous alkylation at N1 and the exocyclic amino group (N6) yielding imidazo-, pyrimido- and diazepino-pyrimidine derivs. The pyrimidopyrimidine derivs. can subsequently be cyclized using hexamethyldisilazane at high temp. affording an easy, convenient and general access to tricyclic pyrimido[1,2,3-cd]purinediones. Alternatively, 3-substituted 6-amino-5-benzylideneaminouracil derivs. can be reacted with 1,3-dibromopropane followed by an oxidative cyclization using thionyl chloride to obtain the desired tricyclic pyrimido[1,2,3-cd]purinediones, which are sterically fixed analogs of pharmacol. active purine derivs.

IT **524944-89-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrimidopurinediones via alkylation of substituted cycloalkylcarboxamidoaminouracil followed by ring closure reaction)

RN 524944-89-6 CAPLUS
CN Cyclopentanecarboxamide, N-(6-butyl-1,2,3,5,6,7-hexahydro-5,7-dioxoimidazo[1,2-c]pyrimidin-8-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:637684 CAPLUS
DOCUMENT NUMBER: 137:185505
TITLE: Preparation of bicyclic pyrimidine selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
INVENTOR(S): Dyer, Richard Dennis; Harter, William Glen; Hicks, James Lester; Johnson, Adam Richard; Li, Jie Jack; Roark, William Howard; Shuler, Kevon Ray
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Applicant's PCT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064599	A1	20020822	WO 2002-IB313	20020130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1362054	A1	20031119	EP 2002-716244	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-268780P P 20010214
WO 2002-IB313 W 20020130
OTHER SOURCE(S): MARPAT 137:185505
GI



I

AB Selective MMP-13 inhibitors are bicyclic pyrimidines (shown as I; e.g. 6-benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester) or a pharmaceutically acceptable salt thereof, wherein R1 is H or alkyl; R2, R3, and R4 include H, halo, alkyl, C.tplbond.C(CH2)m aryl; X is O, S, SO, SO2, CH2, C:O, CHOH, NH, or NR5; and Y = O or S. A compd. of the formula, or a pharmaceutically acceptable salt thereof, is useful for treating cancer or arthritis. IC50 values for various claimed compds. show the selectivity towards MMP-13 vs. other matrix metalloproteinases and the potent MMP-13 inhibitory activity (e.g. 0.0009 .mu.M for 8-methyl-5,7-dioxo-6-[4-(2H-tetrazol-5-yl)benzyl]-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide). Although the methods of prepn. are not claimed, >100 example prepns. are included.

IT **449798-64-5P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester **449798-76-9P**, 6-Benzyl-2-(1-hydroxy-3-phenylpropyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449798-85-0P**, 6-Benzoylthiazolo-5H-[3,2-c]pyrimidine-5,7(6H)-dione **449798-89-4P**, 6-(4-Chlorobenzyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449798-92-9P**, 6-[(Pyridin-4-yl)methyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449799-04-6P 449799-17-1P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid **449799-20-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid methyl ester **449799-37-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-3-ylmethyl)amide **449799-48-8P**, 8-Methylthiazolo[3,2-c]pyrimidine-5,7-dione **449799-49-9P**, 8-Methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid **449799-50-2P**, 4-[2-(4-Methoxybenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449799-55-7P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449799-62-6P**, 4-[8-Methyl-5,7-dioxo-2-[(pyridin-4-ylmethyl)carbamoyl]-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid mono(trifluoroacetate) **449800-21-9P**, 6-Benzyl-8-formyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-26-4P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(intermediate; prepn. of bicyclic pyrimidine selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449798-64-5 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449798-76-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(1-hydroxy-3-phenylpropyl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-85-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-benzoyl- (9CI) (CA INDEX NAME)



RN 449798-89-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(4-chlorophenyl)methyl]-(9CI) (CA INDEX NAME)



RN 449798-92-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-04-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449799-17-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-20-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-37-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-48-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl- (9CI) (CA INDEX NAME)



RN 449799-49-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-50-2 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-55-7 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-62-6 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 449799-61-5
CMF C22 H18 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 449800-21-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-8-formyl-6,7-dihydro-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-26-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



IT **449798-67-8P**, 6-Benzylthiazolo[3,2-c]pyrimidine-5,7-dione
449798-70-3P, 6-Benzyl-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione
449798-72-5P, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-

c]pyrimidine-2-carboxylic acid methyl ester **449798-74-7P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid **449798-84-9P**, Thiazolo[3,2-c]pyrimidine-5,7-dione **449798-87-2P**, 6-(3,4-Dichlorobenzyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449798-93-0P**, 6-(4-Pyridylmethyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-99-6P**, 6-Benzyl-3-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449799-03-5P**, 6-Benzyl-5,7-dioxo-2,3,6,7-tetrahydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid **449799-24-0P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (thiazol-4-ylmethyl)amide **449799-51-3P**, 8-Methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449799-52-4P**, 4-[2-(4-Methoxybenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid tert-butyl ester **449799-56-8P**, 8-Methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-57-9P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid tert-butyl ester **449799-63-7P**, 8-Methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide **449799-64-8P**, 4-[8-Methyl-5,7-dioxo-2-[(pyridin-4-ylmethyl)carbamoyl]-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid tert-butyl ester **449799-69-3P**, 8-Methyl-5,7-dioxo-6-[2-(triphenylmethyl)-2H-tetrazol-5-ylmethyl]-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-10-6P**, 4-[8-Methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid methyl ester **449800-16-2P**, 6-(4-Cyanobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid **449800-22-0P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-25-3P**, 8-Methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of bicyclic pyrimidine selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449798-67-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-70-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-72-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 449798-74-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-84-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione (9CI) (CA INDEX NAME)



RN 449798-87-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449798-93-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N-(phenylmethyl)-6-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-99-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 3-methyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-03-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-24-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-51-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-52-4 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 449799-56-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-57-9 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 449799-63-7 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-64-8 CAPLUS

CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 449799-69-3 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[[2-(triphenylmethyl)-2H-tetrazol-5-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-10-6 CAPLUS

CN Benzoic acid, 4-[(8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-16-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6-[(4-cyanophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-22-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-25-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



IT **449798-68-9P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester **449798-71-4P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid pyridin-4-ylmethyl ester monohydrochloride **449798-75-8P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-77-0P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic

acid biphenyl-4-ylamide **449798-78-1P**, 6-Benzyl-2-(hydroxyphenylmethyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449798-79-2P**, 6-Benzyl-2-(3-phenylpropionyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449798-80-5P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449798-81-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-fluorobenzylamide **449798-82-7P**, 6-Benzoyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-86-1P**, 6-(3,4-Dichlorobenzyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-88-3P**, 6-(4-Chlorobenzyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-90-7P 449798-91-8P**, 6-(4-Pyridylmethyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide monohydrochloride **449798-94-1P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449798-95-2P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449798-97-4P 449798-98-5P**, 6-Benzyl-3-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester **449799-00-2P**, 6-Benzyl-5,7-dioxo-2,3,6,7-tetrahydro-5H-thiazolo[3,2-c]pyrimidine-3-carboxylic acid benzyl ester **449799-02-4P**, 6-Benzyl-5,7-dioxo-2,3,6,7-tetrahydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid pyridin-4-ylmethyl ester monohydrochloride **449799-05-7P**, 6-Benzyl-5,7-dioxo-2,3,6,7-tetrahydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide **449799-06-8P**, 6-Benzyl-1,5,7-trioxo-1,2,3,5,6,7-hexahydro-1.lambda.4-thiazolo[3,2-c]pyrimidine-3-carboxylic acid benzyl ester **449799-07-9P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carbothioic acid benzylamide **449799-08-0P**, 6-Benzyl-3-ethoxy-2,3-dihydrooxazolo[3,2-c]pyrimidine-5,7-dione **449799-11-5P**, 6-Benzyl-3-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid methyl ester **449799-12-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 2,4-dichlorobenzylamide **449799-14-8P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-methylbenzylamide **449799-15-9P**, 6-Benzyl-2-((2E)-1-hydroxy-3-phenylallyl)-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449799-16-0P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-18-2P**, 6-Benzyl-2-(1-hydroxy-3-phenylprop-2-ynyl)-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449799-19-3P**, 6-Benzyl-8-formyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449799-22-8P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (1H-indol-5-ylmethyl)amide **449799-23-9P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (thiazol-4-ylmethyl)amide monohydrochloride **449799-25-1P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide hydrochloride **449799-27-3P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449799-28-4P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide hydrochloride **449799-29-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (imidazo[2,1-b]thiazol-6-ylmethyl)amide **449799-31-9P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (1-methyl-1H-pyrazol-4-ylmethyl)amide **449799-32-0P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid prop-2-ynylamide

449799-33-1P, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-2-ylmethyl)amide **449799-34-2P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2,1,3-benzothiadiazol-5-ylmethyl)amide **449799-36-4P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-difluorobenzylamide **449799-38-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-3-ylmethyl)amide monohydrochloride **449799-39-7P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (piperidin-4-ylmethyl)amide monohydrochloride **449799-40-0P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-fluoro-4-methoxybenzylamide **449799-41-1P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-2-ylmethyl)amide monohydrochloride **449799-42-2P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methylbenzylamide **449799-43-3P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-trifluoromethylbenzylamide **449799-44-4P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-chlorobenzylamide **449799-45-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-trifluoromethoxybenzylamide **449799-46-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylthiazol-4-ylmethyl)amide monohydrochloride **449799-53-5P**, 4-[2-(4-Methoxybenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid sodium salt **449799-54-6P**, 4-[2-(4-Methoxybenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid 2-dimethylaminoethyl ester hydrochloride **449799-58-0P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid Sodium Salt **449799-59-1P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid 2-dimethylaminoethyl ester **449799-60-4P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid 2-dimethylaminoethyl ester monohydrochloride **449799-65-9P**, 4-[8-Methyl-5,7-dioxo-2-[(pyridin-4-ylmethyl)carbamoyl]-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid 2-dimethylaminoethyl ester dihydrochloride **449799-66-0P**, 8-Methyl-6-(2-methylthiazol-4-ylmethyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-67-1P**, 2-Chloro-4-[2-(4-fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid methyl ester **449799-68-2P**, 8-Methyl-5,7-dioxo-6-(2H-tetrazol-5-ylmethyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-70-6P**, 8-Methyl-5,7-dioxo-6-thiazol-2-ylmethyl-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide monohydrochloride **449799-71-7P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]-2-methylbenzoic acid methyl ester **449799-72-8P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]-2-methoxybenzoic acid methyl ester **449799-73-9P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-74-0P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-75-1P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-76-2P**, 8-Methyl-6-[4-(morpholine-4-carbonyl)benzyl]-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-77-3P**, [5-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-

7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]isoxazol-3-yl]carbamic acid methyl ester **449799-78-4P**, 8-Methyl-5,7-dioxo-6-[4-(2H-tetrazol-5-yl)benzyl]-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-79-5P**, 8-Methyl-6-[4-(morpholine-4-carbonyl)benzyl]-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-80-8P**, 6-(6-Fluoroquinolin-2-ylmethyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-81-9P**, 2-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]-5-methoxypyrimidine-4-carboxylic acid methyl ester **449799-84-2P**, 6-But-2-ynyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-85-3P**, 8-Methyl-5,7-dioxo-6-(2-oxo-2H-1-benzopyran-6-ylmethyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-86-4P**, 6-(4-Methanesulfonylbenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-87-5P**, 6-(3-Cyanobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-88-6P**, 6-[2-(4-Chlorobenzenesulfonyl)ethyl]-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-89-7P**, 8-Methyl-5,7-dioxo-6-(4-sulfamoylbenzyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-90-0P**, 6-(4-Cyanobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide monohydrochloride **449799-91-1P**, 8-Methyl-5,7-dioxo-6-(3-oxo-3-phenylpropyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-92-2P**, 8-Methyl-5,7-dioxo-6-(1-phenylethyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-93-3P**, 8-Methyl-5,7-dioxo-6-(2-phenylmethanesulfonylethyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-94-4P**, 6-(5-Cyanopentyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-96-6P**, 6-((E)-But-2-enyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-97-7P**, 8-Methyl-5,7-dioxo-6-((E)-pent-2-enyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-98-8P**, 6-sec-Butyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449799-99-9P**, 8-Methyl-6-(2-methylallyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-00-4P**, 6-(1-Ethylpropyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-01-5P**, 8-Methyl-5,7-dioxo-6-pent-2-ynyl-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-02-6P**, 6-(2-Benzenesulfonylethyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-03-7P**, 8-Methyl-6-(3-methylbut-2-enyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-04-8P**, 6-[2-(4-Fluorobenzenesulfonyl)ethyl]-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-05-9P**, 6-[3-(4-Fluorophenyl)-3-oxopropyl]-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-06-0P**, 6-(2-Benzoylaminoethyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-07-1P**, 8-Methyl-5,7-dioxo-6-(2-phenoxyethyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-08-2P**, 6-(3,4-Dichlorobenzyl)-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449800-09-3P**, 4-[2-(4-Methoxybenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-

ylmethyl]benzoic acid methyl ester **449800-11-7P**, 4-(8-Methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl)benzoic acid tert-butyl ester **449800-12-8P**, 4-[2-(3-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid methyl ester **449800-13-9P**, 4-[2-(4-Fluorobenzylcarbamoyl)-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid methyl ester **449800-15-1P**, 6-(4-Cyanobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-18-4P**, 8-Methyl-6-[4-(morpholine-4-sulfonyl)benzyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449800-19-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-methoxybenzylamide **449800-20-8P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (tetrahydrofuran-2-ylmethyl)amide **449800-23-1P**, 6-Benzyl-8-hydroxymethyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-fluorobenzylamide **449800-24-2P**, 6-(3,4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide hydrochloride **449800-28-6P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carbothioic acid 4-methoxybenzylamide **449800-29-7P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester **449800-30-0P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid benzyl ester **449800-31-1P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449800-32-2P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449800-33-3P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide **449800-35-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-oxazolo[3,2-c]pyrimidine-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449800-36-6P**, 6-Benzyl-8-methyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449800-37-7P**, 6-Benzyl-1,8-dimethyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449800-38-8P**, 6-Benzyl-1,8-dimethyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid benzylamide **449800-39-9P**, 6-Benzyl-1,8-dimethyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449800-40-2P**, 6-Benzyl-1-methyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449800-41-3P**, 6-(4-Methoxybenzyl)-1-methyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449800-42-4P**, 6-(4-Methoxybenzyl)-1,8-dimethyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide **449800-43-5P**, 6-Benzyl-1,8-dimethyl-5,7-dioxo-1,5,6,7-tetrahydroimidazo[1,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzyl ester **449800-44-6P**, 4-[8-Methyl-5,7-dioxo-2-(3-phenylprop-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-45-7P**, 4-[2-[3-(4-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-46-8P**, 4-[2-[3-(4-Fluorophenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-47-9P**, 4-[2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-48-0P**, 4-[2-[3-(3,4-Difluorophenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-49-1P**, 6-Benzyl-8-methyl-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-50-4P**, 6-(3,4-Dichlorobenzyl)-8-methyl-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-51-5P**, 6-(3,4-Dichlorobenzyl)-2-[3-(2-methoxypyridin-4-yl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-52-6P**,

6-Benzyl-8-methyl-2-phenylethynylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-54-8P**, 6-(4-Bromobenzyl)-2-[3-(3-methoxyphenyl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-55-9P**, 4-[2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzenesulfonamide **449800-56-0P**, 4-[2-[3-(3-Fluoro-4-methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-57-1P**, 6-(4-Fluorobenzyl)-8-methyl-2-(3-phenylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-58-2P**, 6-Benzyl-8-methyl-2-(3-phenylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-59-3P**, 6-(3,4-Dichlorobenzyl)-2-[3-(3-methoxyphenyl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-60-6P**, 6-(4-Methanesulfonylbenzyl)-8-methyl-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-61-7P**, 4-[2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzonitrile **449800-62-8P**, 2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-6-[4-(2H-tetrazol-5-yl)benzyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449800-63-9P**, 6-Benzyl-2-[3-(3-methoxyphenyl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-64-0P**, 2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-6-[4-(morpholine-4-carbonyl)benzyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449800-65-1P**, 8-Methyl-6-[4-(morpholine-4-sulfonyl)benzyl]-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-66-2P**, 2-[3-(4-Fluorophenyl)prop-1-ynyl]-8-methyl-6-(2-oxo-2H-1-benzopyran-6-ylmethyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-68-4P**, 2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-6-(2-oxo-2H-1-benzopyran-6-ylmethyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-69-5P**, 4-[8-Methyl-5,7-dioxo-2-(4-phenylbut-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-70-8P**, 4-[8-Methyl-5,7-dioxo-2-(6-phenylhex-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-71-9P**, 4-[8-Methyl-5,7-dioxo-2-(5-phenylpent-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-73-1P**, 4-[8-Methyl-5,7-dioxo-2-(7-phenylhept-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-75-3P**, [4-[2-[3-(3,4-Difluorophenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]phenyl]acetic acid **449800-77-5P**, 6-(3-Fluorobenzyl)-8-methyl-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-79-7P**, 6-(3,4-Difluorobenzyl)-8-methyl-2-(3-pyridin-4-ylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-80-0P**, 6-(3-Fluorobenzyl)-2-[3-(2-methoxypyridin-4-yl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-81-1P**, [3-(8-Methyl-5,7-dioxo-2-phenylethynyl-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl)phenyl]acetic acid **449800-82-2P**, 6-(4-Bromobenzyl)-2-[3-(4-fluoro-3-methoxyphenyl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-83-3P**, 4-[2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]-N,N-dimethylbenzenesulfonamide **449800-84-4P**, 4-[2-[3-(3-Fluoro-4-methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]cyclohexanecarboxylic acid **449800-86-6P**, 6-(3,4-Difluorobenzyl)-2-[3-(3,4-difluorophenyl)prop-1-ynyl]-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-87-7P**, 4-[8-Methyl-5,7-dioxo-2-(3-phenylprop-1-ynyl)-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]cyclohexanecarboxylic acid **449800-88-8P**, 2-Chloro-4-[2-[3-(3-methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid **449800-89-9P**, 2-[3-(4-Fluorophenyl)prop-1-ynyl]-6-(4-methanesulfonylbenzyl)-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione **449800-90-2P**, 4-[2-[3-(4-Fluoro-3-methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzonitrile **449800-91-3P**, [3-[2-[3-(4-Fluoro-3-methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]phenyl]acetic acid **449800-92-4P**, [4-[2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-5,7-

dioxo-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]phenyl]acetic acid **449800-93-5P**, 6-(3,4-Difluorobenzyl)-8-methyl-2-(3-phenylprop-1-ynyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-94-6P**, 2-[3-(3-Methoxyphenyl)prop-1-ynyl]-8-methyl-6-[4-(thiomorpholine-4-carbonyl)benzyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449800-95-7P**, 8-Methyl-2-(3-pyridin-4-ylprop-1-ynyl)-6-[4-(thiomorpholine-4-sulfonyl)benzyl]thiazolo[3,2-c]pyrimidine-5,7-dione **449800-96-8P**, 2-[3-(4-Fluoro-3-methoxyphenyl)prop-1-ynyl]-8-methyl-6-(2-oxo-2H-1-benzopyran-6-ylmethyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-97-9P**, 2-[3-(3-Methoxy-4-methylphenyl)prop-1-ynyl]-8-methyl-6-(2-oxo-2H-1-benzopyran-6-ylmethyl)thiazolo[3,2-c]pyrimidine-5,7-dione **449800-98-0P**, 5,7-Dioxo-6-pyridin-4-ylmethyl-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide hydrochloride **449801-00-7P**, 4-[8-Methyl-5,7-dioxo-2-[(pyridin-4-ylmethyl)carbamoyl]-7H-thiazolo[3,2-c]pyrimidin-6-ylmethyl]benzoic acid trifluoroacetic acid salt **449801-01-8P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-fluorobenzylamide **449801-02-9P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449801-03-0P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methylbenzylamide **449801-04-1P**, 8-Methyl-5,7-dioxo-6-pyridin-4-ylmethyl-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid benzylamide **449801-05-2P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-4-ylmethyl)amide **449801-06-3P**, 6-(4-Methoxybenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449801-07-4P**, 8-Methyl-5,7-dioxo-6-((pyridin-4-yl)methyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzylamide **449801-08-5P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-09-6P**, 6-(4-Methanesulfonylbenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-10-9P**, 8-Methyl-5,7-dioxo-6-(4-sulfamoylbenzyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-11-0P**, 6-(4-Dimethylsulfamoylbenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-12-1P**, 8-Methyl-5,7-dioxo-6-pyridin-3-ylmethyl-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-13-2P**, 8-Methyl-5,7-dioxo-6-((pyridin-2-yl)methyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3,4-dimethoxybenzylamide **449801-14-3P**, 6-(3-Methoxybenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 3-methoxybenzylamide **449801-16-5P**, 6-(3-Methoxybenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449801-17-6P**, 6-Benzo[1,3]dioxol-5-ylmethyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (benzo[1,3]dioxol-5-ylmethyl)amide **449801-18-7P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methylsulfanylbenzylamide **449801-19-8P**, 6-Benzyl-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-4-yl)methyl) ester **449801-20-1P**, 6-Benzyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-4-yl)methyl) ester **449801-21-2P**, 8-Methyl-5,7-dioxo-6-((pyridin-4-yl)methyl)-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid 4-methoxybenzyl ester **449801-22-3P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-23-4P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-24-5P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-

dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-25-6P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-26-7P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-27-8P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-28-9P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclic pyrimidine selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449798-68-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449798-71-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, 4-pyridinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-75-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-77-0 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[1,1'-biphenyl]-4-yl-6,7-dihydro-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-78-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(hydroxyphenylmethyl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-79-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(1-oxo-3-phenylpropyl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-80-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-81-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-82-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-benzoyl-6,7-dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-86-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-88-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-90-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-N-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449798-91-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N-(phenylmethyl)-6-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-94-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-95-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-97-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dichlorophenyl)methyl]-

6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-98-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-3-methyl-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449799-00-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449799-02-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, 4-pyridinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-05-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-06-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester, 1-oxide (9CI) (CA INDEX NAME)



RN 449799-07-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carbothioamide, 6,7-dihydro-8-methyl-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-08-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 3-ethoxy-2,3-dihydro-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-11-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-3-methyl-5,7-dioxo-6-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-12-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-14-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(3-methylphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-15-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[(2E)-1-hydroxy-3-phenyl-2-propenyl]-8-methyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 449799-16-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-18-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(1-hydroxy-3-phenyl-2-propynyl)-8-methyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-19-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 8-formyl-6,7-dihydro-N-[(4-methoxyphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-22-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-(1H-indol-5-ylmethyl)-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-23-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-thiazolylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-25-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 449799-27-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-28-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 449799-29-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-(imidazo[2,1-b]thiazol-6-ylmethyl)-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-31-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-32-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-2-propynyl- (9CI) (CA INDEX NAME)



RN 449799-33-1 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(6-methyl-2-pyridinyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-34-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-36-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-38-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-39-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-40-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3-fluoro-4-methoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-(9CI) (CA INDEX NAME)



RN 449799-41-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-42-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(4-methylphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-43-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-44-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-45-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-

6-(phenylmethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-46-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(2-methyl-4-thiazolyl)methyl]-5,7-dioxo-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-53-5 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 449799-54-6 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●x HCl

PAGE 1-B

— OMe

RN 449799-58-0 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 449799-59-1 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

F

RN 449799-60-4 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

F

RN 449799-65-9 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 449799-66-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-[(2-methyl-4-thiazolyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-67-1 CAPLUS
CN Benzoic acid, 2-chloro-4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-68-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-70-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-thiazolylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-71-7 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-72-8 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-73-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-74-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-75-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-76-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]methyl]-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-77-3 CAPLUS
CN Carbamic acid, [5-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-3-isoxazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-78-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-79-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-80-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[(6-fluoro-2-quinolinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-81-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)



10/ 071,032

RN 449799-84-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(2-butynyl)-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-85-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449799-86-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-6-[[4-(methylsulfonyl)phenyl]methyl]-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 449799-87-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-cyanophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-88-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[2-[(4-chlorophenyl)sulfonyl]ethyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-89-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[[4-(aminosulfonyl)phenyl]methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-90-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-cyanophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-91-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(3-oxo-3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 449799-92-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 449799-93-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[2-[(phenylmethyl)sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449799-94-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(5-cyanopentyl)-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-96-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(2E)-2-butenyl-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 449799-97-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2E)-2-pentenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 449799-98-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-(1-methylpropyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-99-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-(2-methyl-2-propenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-00-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(1-ethylpropyl)-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-01-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-pentynyl)- (9CI) (CA INDEX NAME)



RN 449800-02-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[2-(phenylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449800-03-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-(3-methyl-2-butenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-04-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[2-[(4-fluorophenyl)sulfonyl]ethyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-05-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[3-(4-fluorophenyl)-3-oxopropyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-06-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[2-(benzoylamino)ethyl]-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-07-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 449800-08-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-N-[(4-methoxyphenyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-09-3 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-11-7 CAPLUS
CN Benzoic acid, 4-[(8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 449800-12-8 CAPLUS
CN Benzoic acid, 4-[[2-[[[(3-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-13-9 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-15-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-cyanophenyl)methyl]-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-18-4 CAPLUS
CN Morpholine, 4-[[4-[(8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl)methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 449800-19-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(3-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-20-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 449800-23-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-(hydroxymethyl)-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-24-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 449800-28-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carbothioamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-29-7 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449800-30-0 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449800-31-1 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-32-2 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-33-3 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-35-5 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-36-6 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,5,6,7-tetrahydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-37-7 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-1,5,6,7-tetrahydro-1,8-dimethyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-38-8 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, 1,5,6,7-tetrahydro-1,8-dimethyl-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-39-9 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, 1,5,6,7-tetrahydro-N-[(4-methoxyphenyl)methyl]-1,8-dimethyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-40-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, 1,5,6,7-tetrahydro-N-[(4-methoxyphenyl)methyl]-1-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-41-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, 1,5,6,7-tetrahydro-N,6-bis[(4-methoxyphenyl)methyl]-1-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-42-4 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxamide, 1,5,6,7-tetrahydro-6-[(4-methoxyphenyl)methyl]-1,8-dimethyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-43-5 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 1,5,6,7-tetrahydro-1,8-dimethyl-5,7-dioxo-6-(phenylmethyl)-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 449800-44-6 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-(3-phenyl-1-propynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-45-7 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-46-8 CAPLUS
CN Benzoic acid, 4-[[2-[3-(4-fluorophenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-47-9 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-48-0 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3,4-difluorophenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-49-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-6-(phenylmethyl)-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 449800-50-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-dichlorophenyl)methyl]-8-methyl-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 449800-51-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-dichlorophenyl)methyl]-2-[3-(2-methoxy-4-pyridinyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-52-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-2-(phenylethynyl)-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-54-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(4-bromophenyl)methyl]-2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-55-9 CAPLUS
CN Benzenesulfonamide, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-56-0 CAPLUS
CN Benzoic acid, 4-[[2-[3-(3-fluoro-4-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-57-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(4-fluorophenyl)methyl]-8-methyl-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 449800-58-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-6-(phenylmethyl)-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 449800-59-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-dichlorophenyl)methyl]-2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-60-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-6-[[4-(methylsulfonyl)phenyl]methyl]-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 449800-61-7 CAPLUS
CN Benzonitrile, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-62-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-6-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-63-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449800-64-0 CAPLUS
CN Morpholine, 4-[4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 449800-65-1 CAPLUS
CN Morpholine, 4-[[4-[[8-methyl-5,7-dioxo-2-[3-(4-pyridinyl)-1-propynyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 449800-66-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(4-fluorophenyl)-1-propynyl]-8-methyl-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449800-68-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449800-69-5 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-(4-phenyl-1-butynyl)-5H-

thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-70-8 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-(6-phenyl-1-hexynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-71-9 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-(5-phenyl-1-pentynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-73-1 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-(7-phenyl-1-heptynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-75-3 CAPLUS
CN Benzeneacetic acid, 4-[[2-[3-(3,4-difluorophenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-77-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3-fluorophenyl)methyl]-8-methyl-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 449800-79-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-difluorophenyl)methyl]-8-methyl-2-[3-(4-pyridinyl)-1-propynyl]- (9CI) (CA INDEX NAME)



RN 449800-80-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3-fluorophenyl)methyl]-2-[3-(2-methoxy-4-pyridinyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-81-1 CAPLUS
CN Benzeneacetic acid, 3-[[8-methyl-5,7-dioxo-2-(phenylethynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-82-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(4-bromophenyl)methyl]-2-[3-(4-fluoro-3-methoxyphenyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-83-3 CAPLUS
CN Benzenesulfonamide, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 449800-84-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[2-[3-(3-fluoro-4-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-86-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-difluorophenyl)methyl]-2-[3-(3,4-difluorophenyl)-1-propynyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 449800-87-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[8-methyl-5,7-dioxo-2-(3-phenyl-1-propynyl)-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-88-8 CAPLUS

CN Benzoic acid, 2-chloro-4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-89-9 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(4-fluorophenyl)-1-propynyl]-8-methyl-6-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449800-90-2 CAPLUS
CN Benzonitrile, 4-[[2-[3-(4-fluoro-3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-91-3 CAPLUS
CN Benzeneacetic acid, 3-[[2-[3-(4-fluoro-3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-92-4 CAPLUS
CN Benzeneacetic acid, 4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449800-93-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-difluorophenyl)methyl]-8-methyl-2-(3-phenyl-1-propynyl)- (9CI) (CA INDEX NAME)



RN 449800-94-6 CAPLUS
CN Thiomorpholine, 4-[4-[[2-[3-(3-methoxyphenyl)-1-propynyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 449800-95-7 CAPLUS
CN Thiomorpholine, 4-[[4-[[8-methyl-5,7-dioxo-2-[3-(4-pyridinyl)-1-propynyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 449800-96-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(4-fluoro-3-methoxyphenyl)-1-propynyl]-8-methyl-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449800-97-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-[3-(3-methoxy-4-methylphenyl)-1-propynyl]-8-methyl-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449800-98-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N-(phenylmethyl)-6-(4-pyridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 449801-00-7 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 449799-61-5
CMF C22 H18 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 449801-01-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N,6-bis[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-02-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-03-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(4-methylphenyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-04-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-N-(phenylmethyl)-6-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-05-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-06-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N,6-bis[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-07-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-08-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-09-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-6,7-dihydro-8-methyl-6-[[4-(methylsulfonyl)phenyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-10-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[[4-(aminosulfonyl)phenyl]methyl]-N-[(3,4-dimethoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-11-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-6-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-12-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-13-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-14-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N,6-bis[(3-methoxyphenyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-16-5 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-(1,3-benzodioxol-5-ylmethyl)-6,7-dihydro-6-[(3-methoxyphenyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-17-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N,6-bis(1,3-benzodioxol-5-ylmethyl)-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-18-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[[4-(methylthio)phenyl]methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449801-19-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 449801-20-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-

(phenylmethyl)-, 4-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 449801-21-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(4-pyridinylmethyl)-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 449801-22-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-23-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-24-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-25-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-26-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-27-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-28-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-

5,7-dioxo- (9CI) (CA INDEX NAME)



IT **449801-29-0P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-31-4P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-32-5P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-33-6P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-34-7P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-35-8P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-36-9P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-37-0P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-aminopyridin-4-ylmethyl)amide **449801-38-1P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-39-2P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-40-5P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-41-6P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-42-7P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-43-8P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-44-9P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-45-0P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-46-1P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-49-4P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-51-8P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-53-0P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-55-2P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid

(2-ethoxypyridin-4-ylmethyl)amide **449801-57-4P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-59-6P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-ethoxypyridin-4-ylmethyl)amide **449801-61-0P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-63-2P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-65-4P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-67-6P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-69-8P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-71-2P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-74-5P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-76-7P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-78-9P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-80-3P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-82-5P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-84-7P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-86-9P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-88-1P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-90-5P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-hydroxypyridin-3-ylmethyl)amide **449801-92-7P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449801-94-9P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449801-96-1P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449801-98-3P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-00-0P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-02-2P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-04-4P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-06-6P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-09-9P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-11-3P**,

6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-13-5P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-16-8P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-18-0P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-20-4P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449802-22-6P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-24-8P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-26-0P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-29-3P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-31-7P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-33-9P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-35-1P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-37-3P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-39-5P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-41-9P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-43-1P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-45-3P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-47-5P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-49-7P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-51-1P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylpyridin-4-ylmethyl)amide **449802-54-4P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-56-6P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-58-8P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-60-2P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-62-4P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-64-6P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-66-8P**,

6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-68-0P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-70-4P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-73-7P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-75-9P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-77-1P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-79-3P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-81-7P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-83-9P**, 6-(4-Chloro-3-bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methylaminopyridin-4-ylmethyl)amide **449802-85-1P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-3-ylmethyl)amide **449802-87-3P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-3-ylmethyl)amide **449802-89-5P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (pyridin-3-ylmethyl)amide **449802-91-9P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449802-94-2P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449802-96-4P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449802-98-6P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-00-3P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-02-5P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-04-7P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-06-9P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-08-1P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-10-5P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-12-7P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-15-0P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid ((pyridin-3-yl)methyl)amide **449803-17-2P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-19-4P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-21-8P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide

449803-23-0P, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-25-2P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-27-4P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-29-6P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-31-0P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-34-3P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-36-5P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-38-7P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-40-1P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-42-3P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-44-5P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-46-7P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-aminopyridin-3-ylmethyl)amide **449803-48-9P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-53-6P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-56-9P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-58-1P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-60-5P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-62-7P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-64-9P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-66-1P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-69-4P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-71-8P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-73-0P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-76-3P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-78-5P**

, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-80-9P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid

(6-ethoxypyridin-3-ylmethyl)amide **449803-81-0P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-ethoxypyridin-3-ylmethyl)amide **449803-82-1P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-83-2P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-85-4P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-87-6P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-89-8P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-91-2P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-94-5P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-96-7P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449803-99-0P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-00-6P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-02-8P**, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-04-0P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-06-2P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-08-4P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-10-8P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methoxypyridin-3-ylmethyl)amide **449804-12-0P**, 6-(4-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-13-1P**, 6-(4-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-14-2P**, 6-(4-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-16-4P**, 6-(3-Bromo-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-17-5P**, 6-(3-Bromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-19-7P**, 6-(3,4-Dichlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-21-1P**, 6-(4-Bromo-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-23-3P**, 6-(3-Chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-26-6P**, 6-(3-Fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-28-8P**, 6-(3,4-Dibromobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide

449804-29-9P, 6-(4-Bromo-3-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-30-2P**, 6-(3,4-Difluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-32-4P**, 6-(3-Bromo-4-chlorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-33-5P**, 6-(3-Chloro-4-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-34-6P**, 6-(4-Chloro-3-fluorobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (6-methylpyridin-3-ylmethyl)amide **449804-36-8P**, 6-(4-Cyanobenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide **449804-38-0P**, 6-(4-Isopropylsulfamoylbenzyl)-8-methyl-5,7-dioxo-6,7-dihydro-5H-thiazolo[3,2-c]pyrimidine-2-carboxylic acid (2-methoxypyridin-4-ylmethyl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclic pyrimidine selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses)

RN 449801-29-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-31-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-32-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-33-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-34-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-35-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-36-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-37-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-amino-4-pyridinyl)methyl]-6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-38-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-39-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-40-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-ethoxy-4-pyridinyl)methyl]-6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-

dioxo- (9CI) (CA INDEX NAME)



RN 449801-41-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-42-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-43-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-44-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-

fluorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-45-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-46-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(2-ethoxy-4-pyridinyl)methyl]-6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-49-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-51-8 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-53-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-55-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-57-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449801-59-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-N-[(2-ethoxy-4-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-61-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-63-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-65-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-67-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-69-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-71-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-74-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-76-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-78-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-80-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-82-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-84-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-86-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-88-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-90-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-6,7-dihydro-

8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-92-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-94-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-96-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449801-98-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-

fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-00-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-02-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-04-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-06-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-09-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-11-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-13-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449802-16-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-18-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-20-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-22-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-24-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-26-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-29-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-31-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-33-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-35-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-37-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-39-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-41-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-43-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-45-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-47-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-

5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-49-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-51-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(2-methyl-4-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-54-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-56-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-

dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-58-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-60-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-62-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-64-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-66-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-68-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-70-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449802-73-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-75-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-77-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-79-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-81-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-83-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[[2-(methylamino)-4-pyridinyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449802-85-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449802-87-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449802-89-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449802-91-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449802-94-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449802-96-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449802-98-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449803-00-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449803-02-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449803-04-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449803-06-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-

chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 449803-08-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-
6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX
NAME)



RN 449803-10-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-
chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 449803-12-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-
fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)-
(9CI) (CA INDEX NAME)



RN 449803-15-0 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449803-17-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-19-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-21-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449803-23-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-25-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-27-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-29-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-31-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-34-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-36-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-38-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-40-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-42-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-44-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-46-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-amino-3-pyridinyl)methyl]-6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-48-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-53-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-56-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-ethoxy-3-pyridinyl)methyl]-6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-58-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-

5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-60-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-62-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-64-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-66-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-N-

[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-69-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(6-ethoxy-3-pyridinyl)methyl]-6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-71-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-73-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-76-3 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-78-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-80-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-81-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-N-[(6-ethoxy-3-pyridinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449803-82-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-83-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-85-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-87-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-89-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-91-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-94-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-96-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449803-99-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-00-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-02-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-04-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-06-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-08-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-10-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-12-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA

INDEX NAME)



RN 449804-13-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-14-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-16-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-17-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromophenyl)methyl]-6,7-

dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-19-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-21-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-23-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-26-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-28-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dibromophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-29-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromo-3-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-30-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449804-32-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-bromo-4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-33-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-chloro-4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-34-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chloro-3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-N-[(6-methyl-3-pyridinyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-36-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-cyanophenyl)methyl]-6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449804-38-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(2-methoxy-4-pyridinyl)methyl]-8-methyl-6-[[4-[[(1-methylethyl)amino]sulfonyl]phenyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:637472 CAPLUS
DOCUMENT NUMBER: 137:201321
TITLE: Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors
INVENTOR(S): Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064080	A2	20020822	WO 2002-IB447	20020213
WO 2002064080	A3	20021212		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003078276	A1	20030424	US 2002-75069	20020213
EP 1361873	A2	20031119	EP 2002-710275	20020213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-268821P P 20010214
WO 2002-IB447 W 20020213

GI



I



II



III

AB Title compds., I [R1 and R2 together may form a substituted arom. ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclylalkoxy, etc.; R7 = H, MeO, NO2, etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

IT **449798-67-8P**, 6-Benzylthiazolo[3,2-c]pyrimidine-5,7-dione
449798-70-3P 449798-72-5P 449798-74-7P
449799-51-3P 449799-52-4P 449799-63-7P
449799-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449798-67-8 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-70-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-methyl-6-(phenylmethyl)-
(9CI) (CA INDEX NAME)



RN 449798-72-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-
(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 449798-74-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-
(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-51-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-
methoxyphenyl)methyl]-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-52-4 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 449799-63-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-64-8 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **449798-87-2 449799-49-9**

10/ 071,032

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449798-87-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449799-49-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



IT **449798-64-5P 449798-68-9P 449798-71-4P**
449798-75-8P 449798-80-5P 449798-81-6P
449798-82-7P 449798-86-1P 449798-88-3P
449798-90-7P 449798-91-8P 449798-94-1P
449798-95-2P 449798-97-4P 449799-02-4P
449799-05-7P 449799-06-8P 449799-14-8P
449799-16-0P 449799-19-3P 449799-27-3P
449799-34-2P 449799-36-4P 449799-37-5P
449799-38-6P 449799-40-0P 449799-42-2P
449799-43-3P 449799-44-4P 449799-45-5P
449799-50-2P 449799-53-5P 449799-55-7P
449799-58-0P 449799-59-1P 449799-60-4P
449799-62-6P 449799-65-9P 449799-66-0P
449799-67-1P 449799-70-6P 449799-71-7P
449799-72-8P 449799-73-9P 449799-74-0P
449799-76-2P 449799-77-3P 449799-78-4P
449799-79-5P 449799-80-8P 449799-81-9P
449799-84-2P 449799-85-3P 449799-86-4P
449799-87-5P 449799-89-7P 449799-90-0P
449799-93-3P 449799-96-6P 449799-97-7P
449799-98-8P 449800-01-5P 449800-03-7P
449800-04-8P 449800-05-9P 449800-07-1P
449800-08-2P 449800-09-3P 449800-12-8P
449800-13-9P 449800-15-1P 449800-19-5P
451471-31-1P 451471-32-2P 451471-33-3P
451471-34-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 449798-64-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449798-68-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 449798-71-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-, 4-pyridinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-75-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-80-5 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-81-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-82-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-benzoyl-6,7-dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-86-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-88-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-

dihydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-90-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-N-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449798-91-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-5,7-dioxo-N-(phenylmethyl)-6-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449798-94-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-N,6-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449798-95-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(4-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA

INDEX NAME)



RN 449798-97-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-02-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, 4-pyridinylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-05-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-06-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-5,7-dioxo-6-(phenylmethyl)-, phenylmethyl ester, 1-oxide (9CI) (CA INDEX

NAME)



RN 449799-14-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(3-methylphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-16-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-19-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 8-formyl-6,7-dihydro-N-[(4-methoxyphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-27-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-34-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-(2,1,3-benzothiadiazol-5-ylmethyl)-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-36-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3,4-difluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-37-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-38-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(3-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-40-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(3-fluoro-4-methoxyphenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-42-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-N-[(4-methylphenyl)methyl]-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-43-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-44-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 449799-45-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-50-2 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-53-5 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 449799-55-7 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-58-0 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 449799-59-1 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

F

RN 449799-60-4 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

F

RN 449799-62-6 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 449799-61-5
CMF C22 H18 N4 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 449799-65-9 CAPLUS
CN Benzoic acid, 4-[[8-methyl-5,7-dioxo-2-[[(4-pyridinylmethyl)amino]carbonyl]-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 449799-66-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-[(2-methyl-4-thiazolyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-67-1 CAPLUS
CN Benzoic acid, 2-chloro-4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-70-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-thiazolylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-71-7 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-72-8 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-2-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-73-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-74-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-bromophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-76-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]methyl]-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-77-3 CAPLUS
CN Carbamic acid, [5-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-3-isoxazolyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-78-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[[4-(1H-tetrazol-5-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 449799-79-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-80-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[(6-fluoro-2-quinolinyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449799-81-9 CAPLUS
CN 4-Pyrimidinecarboxylic acid, 2-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-5-methoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 449799-84-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(2-butynyl)-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 449799-85-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[(2-oxo-2H-1-benzopyran-6-yl)methyl]- (9CI) (CA INDEX NAME)



RN 449799-86-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-6-[[4-(methylsulfonyl)phenyl]methyl]-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-87-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3-cyanophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-89-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[[4-(aminosulfonyl)phenyl]methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-90-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-cyanophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 449799-93-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-[2-[(phenylmethyl)sulfonyl]ethyl]- (9CI) (CA INDEX NAME)



RN 449799-96-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-(2E)-2-butenyl-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 449799-97-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2E)-2-pentenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 449799-98-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-(1-methylpropyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-01-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-pentynyl)- (9CI) (CA INDEX NAME)



RN 449800-03-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-6-(3-methyl-2-butenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-04-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[2-[(4-fluorophenyl)sulfonyl]ethyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-05-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6-[3-(4-fluorophenyl)-3-oxopropyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-07-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-6-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 449800-08-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(3,4-dichlorophenyl)methyl]-6,7-dihydro-N-[(4-methoxyphenyl)methyl]-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-09-3 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-12-8 CAPLUS
CN Benzoic acid, 4-[[2-[[[(3-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-13-9 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-fluorophenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 449800-15-1 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-cyanophenyl)methyl]-N-[(4-fluorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 449800-19-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(3-methoxyphenyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 451471-31-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-8-methyl-5,7-dioxo-6-(phenylmethyl)-N-(4-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 451471-32-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6,7-dihydro-N-[(6-methoxy-3-pyridinyl)methyl]-8-methyl-5,7-dioxo-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 451471-33-3 CAPLUS
CN Benzoic acid, 4-[[2-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-8-methyl-5,7-dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-yl]methyl]-, 2-(dimethylamino)ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● HCl

PAGE 1-B

RN 451471-34-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-2-carboxamide, 6-[(4-chlorophenyl)methyl]-6,7-dihydro-8-methyl-5,7-dioxo-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 6 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN

10/ 071,032

ACCESSION NUMBER: 2002:612954 CAPLUS
DOCUMENT NUMBER: 138:39127
TITLE: Synthesis of 1-(2-hydroxy-3-methoxypropyl)uracils and their activity against L1210 and macrophage RAW 264.7 cells
AUTHOR(S): Copik, Alicja; Suwinski, Jerzy; Walczak, Krzysztof; Bronikowska, Joanna; Czuba, Zenon; Krol, Wojciech
CORPORATE SOURCE: Institute of Organic Chemistry and Technology, Silesian University of Technology, Gliwice, 44-100, Pol.
SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2002), 21(4 & 5), 377-383
CODEN: NNNAFY; ISSN: 1525-7770
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:39127

AB The title compds. were obtained from appropriate 5-substituted uracil derivs. and 1,2-oxy-3-methoxypropane in the presence of sodium hydride. Under similar conditions 5-iodouracil gave 2-methoxymethyl-2,3-dihydro-oxazolo[3,2-c]pyrimidine-5,7-dione as a result of intramol. cine type nucleophilic substitution. Cytotoxicity of 1-(2-hydroxy-3-methoxypropyl)-5-substituted uracil derivs. against L1210 and macrophage RAW 264.7 cells in vitro was examd.

IT **478702-48-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of 2-methoxymethyl-2,3-dihydro-oxazolo[3,2-c]pyrimidine-5,7-dione from 5-iodouracil as a result of intramol. cine type nucleophilic substitution)
RN 478702-48-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(methoxymethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:900170 CAPLUS
DOCUMENT NUMBER: 136:294794
TITLE: Asymmetric hetero-Diels-Alder reactions. Reactions of oxazolo[3,2-c]pyrimidines
AUTHOR(S): Elliott, Mark C.; Kruiswijk, Elbertus; Willock, David J.
CORPORATE SOURCE: Department of Chemistry, Cardiff University, Cardiff, CF10 3TB, UK
SOURCE: Tetrahedron (2001), 57(51), 10139-10146
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

10/ 071,032



I

AB Diastereomerically pure oxazolo[3,2-c]pyrimidines, e.g. I, can be readily prepd. by the reaction of alkenyloxazolines with isocyanates. The mechanism of this transformation was investigated computationally by MOPAC (PM3 parameterization). These compds. undergo epimerization upon prolonged heating, a reaction which is consistent with the proposed stepwise mechanism. Hydrolysis reactions of these compds. were investigated.

IT **409059-32-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(investigations of asym. hetero-Diels-Alder reactions to give oxazolo[3,2-c]pyrimidines)

RN 409059-32-1 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-8-carboxamide, 3-ethyl-2,3,6,7-tetrahydro-5,7-dioxo-N,6-diphenyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:667064 CAPLUS

DOCUMENT NUMBER: 127:358834

TITLE: 5,6-Dihydropyrrolo[1,2-c]pyrimidine-1,3(2H,5H)-diones as annulated analogs of the anti-HIV compound MKC-442 [6-benzyl-1-(ethoxymethyl)-5-isopropyluracil]

AUTHOR(S): Danel, Krzysztof; Pedersen, Erik B.; Nielsen, Claus

CORPORATE SOURCE: Department Chemistry, Odense University, Odense, DK-5230, Den.

SOURCE: Synthesis (1997), (9), 1021-1026
CODEN: SYNTBF; ISSN: 0039-7881

PUBLISHER: Thieme

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:358834

AB Annulated analogs of the anti-HIV compd. MKC-442 were synthesized from 6-benzoyl-5-ethyl-2,4-dimethoxypyrimidine (I) by reaction with Zn/NH4Cl and 3-bromopropene. The intermediate homoallylic alc. is subjected to a ring-closure reaction by treatment with Br2 either directly or after

O-benzylation to give 5,6-dihydropyrrolo[1,2-c]pyrimidinones. No activity against HIV was obsd., neither for the annulated analogs nor the derivs. synthesized from I. Only compd. I showed activity against HIV-1.

IT **198555-48-5P 198555-52-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of hydropyrrolopyrimidinediones as MKC-442 analogs without anti-HIV activity)

RN 198555-48-5 CAPLUS
CN Pyrrolo[1,2-c]pyrimidine-1,3(2H,5H)-dione, 7-(bromomethyl)-4-ethyl-6,7-dihydro-5-hydroxy-5-phenyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 198555-52-1 CAPLUS
CN Pyrrolo[1,2-c]pyrimidine-1,3(2H,5H)-dione, 7-(bromomethyl)-4-ethyl-6,7-dihydro-5-hydroxy-5-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 9 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:211764 CAPLUS
DOCUMENT NUMBER: 124:261035
TITLE: Condensed imidazole compounds, their production, and use as adhesion molecule expression inhibitors.
INVENTOR(S): Takatani, Muneo; Ikeda, Hitoshi; Iida, Kyoko; Abe, Hidenori
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 238 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535296	A1	19951228	WO 1995-JP1192	19950615

W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN

10/ 071,032

RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2191979	AA	19951228	CA 1995-2191979	19950615	
AU 9526826	A1	19960115	AU 1995-26826	19950615	
EP 767790	A1	19970416	EP 1995-921968	19950615	
EP 767790	B1	20011212			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
CN 1151161	A	19970604	CN 1995-193713	19950615	
CN 1046725	B	19991124			
AT 210663	E	20011215	AT 1995-921968	19950615	
JP 08319288	A2	19961203	JP 1995-151844	19950619	
US 5840732	A	19981124	US 1996-481391	19961206	

PRIORITY APPLN. INFO.: JP 1994-137600 A 19940620
JP 1995-64128 A 19950324
WO 1995-JP1192 W 19950615

OTHER SOURCE(S): MARPAT 124:261035

GI



AB The invention provides new condensed imidazoles possessing adhesion mol. expression-inhibiting activity. This invention also provides therapeutic and prophylactic agents for diabetic nephritis and/or autoimmune disease, and immunosuppressants for organ transplantation. The compds. have formula I [wherein X = bond, S(O)m, O, NR3a, Alk, AlkW, or SAlkW; W = O, NR3a, COO or OCONR3a; Y = CH or N; B = groups Q1 or Q2; B1 = (CH2)f or CZ1Z2; f = 1-6; Z1 = O or S; Z2 = O, S, Alk1, Alk1S, or NR3b; Alk, Alk1 = (un)substituted hydrocarbondiyl; R3a, R3b = H, (un)substituted hydrocarbyl; R4, R5 = H, (esterified) CO2H, (un)substituted amino or heterocyclyl, W1, SW1, OW1; W = (un)substituted hydrocarbyl; or R4R5 may form ring; R6, R7 = (un)substituted hydrocarbyl or heterocyclyl; R8 = H, (un)substituted hydrocarbyl or heterocyclyl, NO2, cyano, (un)protected NH2, halo, acyl; m= 0-2]. For example, cyclocondensation of benzylurea with di-Et phenylmalonate gave 83% 3-benzyl-5-phenylpyrimidine-2,4,6(1H,3H)-trione. This was converted to the 6-chloro deriv. (95%), N1-alkylated with Br(CH2)3Cl (74%), cyclized with Na hydrosulfide (27%), and debenzylated (32%) to give pyrimidothiazinedione deriv. II. This underwent alkylation with Br(CH2)4Cl (65%), S-oxidn. to the dioxide (87%), coupling with 5-mercaptoimidazo[1,2-a]pyridine (44%), and acidification

with HCl (100%), to give title compd. III as the HCl salt. At 10 mg/kg/day i.p. in the mouse homologous skin transplantation test, III.HCl increased the mean rejection day from 13.5 (control) to 27.0.

IT **175143-18-7P 175143-19-8P 175143-20-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of condensed imidazoles as adhesion mol. expression inhibitors)

RN 175143-18-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(4-chlorobutyl)-2,3-dihydro-8-phenyl- (9CI) (CA INDEX NAME)



RN 175143-19-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(4-chlorobutyl)-2,3-dihydro-8-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 175143-20-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(4-chlorobutyl)-2,3-dihydro-8-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



IT **175141-94-3P 175141-95-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of condensed imidazoles as adhesion mol. expression inhibitors)

RN 175141-94-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-[4-(imidazo[1,2-a]pyridin-5-ylthio)butyl]-8-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

10/ 071,032



RN 175141-95-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-[4-(imidazo[1,2-a]pyridin-5-ylthio)butyl]-8-phenyl-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 10 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:716116 CAPLUS
DOCUMENT NUMBER: 123:313909
TITLE: Tetaazaacenaphthene and tetraazaphenalene derivatives: a new class of hepatoprotectants. Part IV
AUTHOR(S): Ram, Vishnu; Goel, Atul; Patnaik, G. K.
CORPORATE SOURCE: Medicinal Chem. Div., Central Drug Res. Inst., Lucknow, 226 001, India
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(14), 1541-4
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis and hepatoprotective activity of imidazolidine, hexahydropyrimidine, imidazo[3,2-c]pryimidine, tetraazaacenaphthene and

tetraazaphenalene derivs. were described. Some of the screened compds. have shown a very significant activity.

IT **170029-98-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of pyrimidine derivs. as hepatoprotectants)

RN 170029-98-8 CAPLUS

CN Imidazo[1,2-c]pyrimidine-1(5H)-carbothioamide, 8-cyano-N,6-diethyl-2,3,6,7-tetrahydro-7-oxo-5-thioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 11 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:319155 CAPLUS

DOCUMENT NUMBER: 122:133114

TITLE: A new class of potent hypolipemic agents raising high-density lipoproteins. Synthesis, reactions and pharmacological properties

AUTHOR(S): Furrer, H.; Granzer, E.; Wagner, R.

CORPORATE SOURCE: Preclinical Res., Med. Chem., Hoechst AG Werk Kalle-Albert, Wiesbaden, D-65174, Germany

SOURCE: European Journal of Medicinal Chemistry (1994), 29(11), 819-29
CODEN: EJMCA5; ISSN: 0223-5234

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of thiazolo[3,2-c]pyrimidine-5,7-diones has been synthesized. Results from in vivo evaluations in rats have shown that many of these compds. produce a pronounced increase of HDL cholesterol and a marked decrease of LDL and VLDL cholesterol. The most potent compd., at 30 mg/kg/d per os over 7 d in male rats, led to the following changes: HDL cholesterol +101%, LDL cholesterol -40%, and VLDL cholesterol -98%. These effects may result in antiatherosclerotic properties in these compds. The prepn. of 7-amino-2,3-dihydrothiazolo[3,2-a]pyrimidine-5-ones and 5-amino-2,3-dihydrothiazolo[3,2-a]pyrimidin-7-ones is described.

IT **39931-58-3P 149221-42-1P 149221-51-2P 149221-53-4P 161094-28-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of thiazolopyrimidinediones as hypolipemic agents raising high-d. lipoproteins)

RN 39931-58-3 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 149221-42-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-51-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-oxopropyl)- (9CI) (CA INDEX NAME)



RN 149221-53-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro- (9CI) (CA INDEX NAME)



RN 161094-28-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxaldehyde, 2,3,6,7-tetrahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



IT **133801-54-4P 133801-57-7P 149221-43-2P**
149221-45-4P 149221-46-5P 149221-47-6P
149221-48-7P 149221-49-8P 149221-50-1P
149221-52-3P 149221-54-5P 149221-57-8P
149221-59-0P 161094-27-5P 161094-29-7P
161094-30-0P 161094-31-1P 161094-32-2P
161094-33-3P 161094-34-4P 161094-35-5P
161094-36-6P 161094-37-7P 161094-38-8P
161094-39-9P 161094-40-2P 161094-41-3P
161094-42-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of thiazolopyrimidinediones as hypolipemic agents raising high-d. lipoproteins)

RN 133801-54-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



RN 133801-57-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 149221-43-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo-, 1-oxide (9CI) (CA INDEX NAME)



RN 149221-45-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-.alpha.-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-46-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 8-ethyl-2,3-dihydro-.alpha.-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-47-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 149221-48-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-methylpropyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 149221-49-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-propynyl)-(9CI) (CA INDEX NAME)



RN 149221-50-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-.alpha.,8-dimethyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-52-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 149221-54-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 149221-57-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 149221-59-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-, 1-oxide (9CI) (CA INDEX NAME)



RN 161094-27-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carbonitrile, 2,3,6,7-tetrahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 161094-29-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-nitro- (9CI) (CA INDEX NAME)



RN 161094-30-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-acetyl- (9CI) (CA INDEX NAME)



RN 161094-31-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(1-piperidinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 161094-32-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(4-morpholinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 161094-33-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-[(4-chlorophenyl)methyl]-(9CI) (CA INDEX NAME)



RN 161094-34-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 161094-35-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-acetonitrile, 2,3-dihydro-5,7-dioxo-(9CI) (CA INDEX NAME)



RN 161094-36-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-pentanenitrile, 2,3-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 161094-37-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 161094-38-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(2-methoxyethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 161094-39-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 8-ethyl-2,3-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



10/ 071,032

RN 161094-40-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-(ethoxymethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 161094-41-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 161094-42-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxaldehyde, 2,3,6,7-tetrahydro-5,7-dioxo-, 8-oxime (9CI) (CA INDEX NAME)



L3 ANSWER 12 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:315239 CAPLUS
DOCUMENT NUMBER: 122:160593
TITLE: Unusual annelation of 2-methylimidazoline by aryl isocyanates
AUTHOR(S): Korshin, E. E.; Sabirova, L. I.; Levin, Ya. A.
CORPORATE SOURCE: A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan, 420083, Russia
SOURCE: Izvestiya Akademii Nauk, Seriya Khimicheskaya (1994), (8), 1509-10
CODEN: IASKEA
PUBLISHER: Institut Organicheskoi Khimii im. N. D. Zelinskogo Rossiiskoi Akademii Nauk
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 122:160593
GI



I

AB Reactions of 2-methylimidazoline with RNCO (R = Ph, p-tolyl, 1-naphthyl) resulted in annelation of the heterocycle to yield imidazo[1,2-c]pyrimidine-5,7-diones (I).

IT **21418-77-9P 161155-53-9P 161155-54-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21418-77-9 CAPLUS

CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 1,2,3,5,6,7-hexahydro-5,7-dioxo-N,6-diphenyl- (9CI) (CA INDEX NAME)



RN 161155-53-9 CAPLUS

CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 1,2,3,5,6,7-hexahydro-N,6-bis(4-methylphenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 161155-54-0 CAPLUS

CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 1,2,3,5,6,7-hexahydro-N,6-di-1-naphthalenyl-5,7-dioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 13 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:539262 CAPLUS
DOCUMENT NUMBER: 119:139262
TITLE: Preparation and arteriosclerosis activity of thiazolopyrimidinediones and their intermediates
INVENTOR(S): Furrer, Harald; Gebert, Ulrich; Granzer, Ernold
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4137437	A1	19930519	DE 1991-4137437	19911114

PRIORITY APPLN. INFO.: DE 1991-4137437 19911114
OTHER SOURCE(S): MARPAT 119:139262
GI



I

AB Title compds. I [R1 = H, C1-5 alkyl, (.omega.-1)(C3-5)-alkenyl, (.omega.-1)(C3-4)-alkynyl, .omega.-cyano-(C1-5)-alkyl, (.omega.-1)-cyano(C2-5)-alkyl, .omega.-methoxy-(C1-3)-alkyl, .omega.-ethoxy-(C1-3)-alkyl, (.omega.-1)-oxo-(C3-4)-alkyl, (.omega.-1)-hydroxy-(C3-4)-alkyl, R2 = H, C1-3 alkyl, p-chlorobenzyl; n = 0, 1] and their prepn., certain intermediates, use for treating arteriosclerosis, and drugs contg. them are claimed. Synthetic examples, antihypercholesterinemic activities, and related lipoprotein exptl. data are given.

10/ 071,032

IT **39931-58-3P 149221-53-4P 149221-54-5P**
149221-57-8P 149221-59-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of arteriosclerosis inhibitor)

RN 39931-58-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 149221-53-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro- (9CI) (CA INDEX NAME)



RN 149221-54-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 149221-57-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 149221-59-0 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-, 1-oxide (9CI) (CA INDEX NAME)



IT **133801-61-3P 149221-42-1P 149221-43-2P**
149221-44-3P 149221-45-4P 149221-46-5P
149221-47-6P 149221-48-7P 149221-49-8P
149221-50-1P 149221-51-2P 149221-52-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as arteriosclerosis inhibitor)

RN 133801-61-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 149221-42-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-43-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-butanenitrile, 2,3-dihydro-5,7-dioxo-, 1-oxide (9CI) (CA INDEX NAME)



RN 149221-44-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-8-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-45-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-.alpha.-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-46-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 8-ethyl-2,3-dihydro-.alpha.-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-47-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 149221-48-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-methylpropyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 149221-49-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-propynyl)-(9CI) (CA INDEX NAME)



RN 149221-50-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-6(7H)-propanenitrile, 2,3-dihydro-.alpha.,8-dimethyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 149221-51-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-oxopropyl)-(9CI) (CA INDEX NAME)



RN 149221-52-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 14 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:228938 CAPLUS
DOCUMENT NUMBER: 114:228938
TITLE: Preparation of pyrimido[6,1-b][1,3]thiazine-6,8-diones and related compounds as drugs
INVENTOR(S): Naka, Takehiko; Saijo, Taketoshi; Shimamoto, Norio; Suno, Masahiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 74 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 404525	A2	19901227	EP 1990-306691	19900619
EP 404525	A3	19911009		
EP 404525	B1	19960515		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5082838	A	19920121	US 1990-538071	19900613
AT 138069	E	19960615	AT 1990-306691	19900619
CA 2019369	AA	19901221	CA 1990-2019369	19900620
CA 2019369	C	20010724		
JP 03086887	A2	19910411	JP 1990-161446	19900621
JP 3096047	B2	20001010		

PRIORITY APPLN. INFO.: JP 1989-156725 A 19890621
OTHER SOURCE(S): MARPAT 114:228938
GI



I II

AB The title compds. I [R1 = aliph., aralkyl, (substituted) aryl; R2 = H, (substituted) aliph., aryl, amino, CHO, NO2, halo; A = (substituted) hydrocarbylene; m = 0-2] were prepd. Thus, NaSH was added to 6-chloro-1-(3-chloropropyl)-5-phenyl-3-propyluracil in DMF with ice cooling and the mixt. was stirred 1 h to give 9-phenyl-7-propyl-3,4-dihydro-2H,6H-pyrimido[6,1-b][1,3]thiazine-6,8(7H)-dione. The latter was treated with (F3CCO)2O/Et3N in CH2Cl2 to give the 2-hydroxy deriv., which was refluxed with 4-MeC6H4SO3H in PhMe to give title compd. II. II at 10-5M gave 90% inhibition of endothelin-induced contraction of porcine

coronary artery rings.

IT **133801-54-4P 133801-55-5P 133801-56-6P**
133801-57-7P 133801-58-8P 133801-59-9P
133801-60-2P 133801-61-3P 133801-62-4P
133801-63-5P 133801-83-9P 133801-86-2P
133801-89-5P 133801-90-8P 133801-91-9P
133801-96-4P 133801-97-5P 133802-06-9P
133802-07-0P 133802-08-1P 133802-09-2P
133802-10-5P 133802-26-3P 133802-27-4P
133802-34-3P 133802-36-5P 133802-39-8P
133802-41-2P 133802-42-3P 133802-43-4P
133802-44-5P 133802-48-9P 133802-49-0P
133802-50-3P 133802-51-4P 133802-52-5P
133802-53-6P 133802-60-5P 133802-61-6P
133802-64-9P 133802-65-0P 133802-67-2P
133802-68-3P 133802-69-4P 133802-70-7P
133803-01-7P 133803-18-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as endothelin inhibitor, IL-1 synthesis inhibitor, and NGF synthesis stimulator)

RN 133801-54-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



RN 133801-55-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-methyl-8-phenyl- (9CI) (CA INDEX NAME)



RN 133801-56-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-ethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 133801-57-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-propyl- (9CI)

10/ 071,032

(CA INDEX NAME)



RN 133801-58-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-phenyl-6-propyl-
(9CI) (CA INDEX NAME)



RN 133801-59-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-butyl-2,3-dihydro- (9CI)
(CA INDEX NAME)



RN 133801-60-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-butyl-2,3-dihydro-8-phenyl-
(9CI) (CA INDEX NAME)



RN 133801-61-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-(2-propenyl)-
(9CI) (CA INDEX NAME)



RN 133801-62-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-phenyl- (9CI) (CA INDEX NAME)



RN 133801-63-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6,8-diphenyl- (9CI) (CA INDEX NAME)



RN 133801-83-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-nitro-6-propyl- (9CI) (CA INDEX NAME)



RN 133801-86-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-6-propyl- (9CI) (CA INDEX NAME)



RN 133801-89-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-ethyl-2,3-dihydro-8-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 133801-90-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-butyl-2,3-dihydro-8-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 133801-91-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6,8-diphenyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 133801-96-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-propyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 133801-97-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-phenyl-6-propyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 133802-06-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-methyl-8-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 133802-07-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-ethyl-2,3-dihydro-8-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 133802-08-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-phenyl-6-propyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 133802-09-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-butyl-2,3-dihydro-8-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 133802-10-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6,8-diphenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 133802-26-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-hydroxy-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-27-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(acetyloxy)-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-34-3 CAPLUS
CN Formamide, N-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)- (9CI) (CA INDEX NAME)



RN 133802-36-5 CAPLUS
CN Acetamide, N-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)- (9CI) (CA INDEX NAME)



RN 133802-39-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-amino-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-41-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(dimethylamino)-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-42-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(butylamino)-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-43-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(dibutylamino)-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-44-5 CAPLUS
CN Butanamide, N-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)- (9CI) (CA INDEX NAME)



RN 133802-48-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxaldehyde, 2,3,6,7-tetrahydro-5,7-dioxo-6-propyl- (9CI) (CA INDEX NAME)

10/ 071,032



RN 133802-49-0 CAPLUS
CN Propanedinitrile, [(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)methylene]- (9CI) (CA INDEX NAME)



RN 133802-50-3 CAPLUS
CN 2-Propenoic acid, 3-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)-, ethyl ester, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 133802-51-4 CAPLUS
CN 2-Propenenitrile, 3-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 133802-52-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-(1-hexenyl)-2,3-dihydro-6-propyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 133802-53-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-(2-phenylethenyl)-6-propyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 133802-60-5 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-[(dimethylamino)methyl]-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-61-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-(1-piperidinylmethyl)-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-64-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-(hydroxymethyl)-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-65-0 CAPLUS
CN Piperidine, 1-[1-oxo-3-(2,3,6,7-tetrahydro-5,7-dioxo-6-propyl-5H-thiazolo[3,2-c]pyrimidin-8-yl)-2-propenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 133802-67-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(chloromethyl)-2,3-dihydro-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-68-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(chloromethyl)-2,3-dihydro-8-phenyl-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-69-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-[(phenylthio)methyl]-6-propyl- (9CI) (CA INDEX NAME)



RN 133802-70-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-methylene-6-propyl- (9CI) (CA INDEX NAME)



RN 133803-01-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-phenyl-6-propyl- (9CI) (CA INDEX NAME)



RN 133803-18-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-6-methyl-8-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



L3 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:23653 CAPLUS
DOCUMENT NUMBER: 114:23653
TITLE: Stereocontrolled conversion of 1-(3-hydroxyprop-1-enyl)uracil isomers into polyfunctional 3,9-propano- and 3,9(9,3)-propeno-aza-9H-xanthines
AUTHOR(S): Jokic, Milan; Skaric, Vinko
CORPORATE SOURCE: Lab. Stereochem. Nat. Prod., "Ruder Boskovic" Inst., Zagreb, 41001, Yugoslavia
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1990), (8), 2225-32
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:23653
GI



II



III



IV

AB With DBU, 1-(3-azido-, and 1-(3-trityloxy-2-methylsulfonyloxypropyl)-3-methyluracil underwent elimination to give the E- and Z-prop-1-enyl isomers. Treatment of (E)- and (Z)-1-(3-hydroxyprop-1-enyl)-3-methyluracil with Br2-MeOH generated asym. centers at C-1' and C-2', providing threo- and erythro-5-bromo-1-(2-bromo-3-hydroxy-1-methoxypropyl)-3-methyluracil (I). Conversion of I into erythro- and threo-5-bromo-1-(2,3-epoxy-1-methoxypropyl)-3-methyluracil was accomplished under mild DBU-elimination conditions. The reaction of the diastereoisomeric epoxides with NaN3-DMF produced erythro- and threo-1-(3-azido-2-hydroxy-1-methoxypropyl)-3-methyluracil. These isomers underwent two types of intramol. cyclization reaction, which gave trans- and cis-2-azidomethyl-3-methoxy-6-methyl-2,3-dihydrooxazolo[3,2-c]pyrimidines-5,7-dione (II) and cis- and trans-11-hydroxy-12-methoxy-1-methyl-3,9-propano-8-aza-9H-xanthine (III). The elimination reaction of 12-methoxy-1-methyl-11-methylsulfonyloxy-3,9-propano-8-aza-9H-xanthine with DBU gave 12-methoxy-1-methyl-9,3-propeno-8-aza-9H-xanthine (IV). Its 3,9-propeno isomer was obtained from a DBU-elimination of 11-bromo-10-methoxy-1-methyl-3,9-propano-8-aza-9H-xanthine. IV was converted into 11-bromo-10,12-dimethoxy-1-methyl-3,9-propano-8-aza-9H-xanthine on treatment with Br-MeOH.

IT **130967-43-0P 130967-44-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 130967-43-0 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(azidomethyl)-2,3-dihydro-3-methoxy-6-methyl-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 130967-44-1 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(azidomethyl)-2,3-dihydro-3-methoxy-6-methyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 16 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:407424 CAPLUS
DOCUMENT NUMBER: 111:7424
TITLE: Preparation of nitro-substituted heterocyclic compounds as insecticides
INVENTOR(S): Shiokawa, Kozo; Tsuboi, Shinichi; Sasaki, Shoko; Moriya, Koichi; Hattori, Yumi; Shibuya, Katsuhiko
PATENT ASSIGNEE(S): Nihon Tokushu Noyaku Seizo K. K., Japan
SOURCE: Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 296453	A2	19881228	EP 1988-109426	19880614
EP 296453	A3	19890920		
EP 296453	B1	19970813		
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 64003184	A2	19890106	JP 1987-157528	19870626
JP 07010865	B4	19950208		
US 4876263	A	19891024	US 1988-208421	19880617
BR 8803133	A	19890208	BR 1988-3133	19880624
HU 47392	A2	19890328	HU 1988-3213	19880624
US 4960780	A	19901002	US 1989-353370	19890517
US 5036082	A	19910730	US 1990-510509	19900418
US 5122527	A	19920616	US 1991-699068	19910513
US 5231098	A	19930727	US 1992-823240	19920121
US 5290779	A	19940301	US 1992-998337	19921230
US 5366976	A	19941122	US 1993-126950	19930927
US 5472960	A	19951205	US 1994-291236	19940816
US 5622956	A	19970422	US 1995-461903	19950605

PRIORITY APPLN. INFO.: JP 1987-157528 19870626
US 1988-208421 19880617
US 1989-353370 19890517
US 1990-510509 19900418
US 1991-699068 19910513
US 1992-823240 19920121
US 1992-998337 19921230
US 1993-126950 19930927
US 1994-291236 19940816
OTHER SOURCE(S): CASREACT 111:7424; MARPAT 111:7424
GI



I



II

AB The title compds. [I; A = (un)substituted (CH2)2-3; B = atoms to complete a ring; R = H, alkyl; Z = (un)substituted aryl, heterocyclyl] were prepd. 2-Nitromethylene-3-(2-chloro-5-pyridylmethyl)imidazolidine was refluxed 20 h with HC.tplbond.CCO2Me in MeOH to give title compd. II (R1 = H). II (R1 = CO2Et) gave 100% kill of organophosphorus- and carbamate-resistant Myzus persicae when sprayed at 200 ppm.

IT **121050-36-0P 121050-38-2P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as insecticide)

RN 121050-36-0 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 1-[(6-chloro-3-pyridinyl)methyl]-2,3-dihydro-8-nitro- (9CI) (CA INDEX NAME)



RN 121050-38-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-7(1H)-one, 1-[(6-chloro-3-pyridinyl)methyl]-2,3,5,6-tetrahydro-8-nitro-5-thioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 17 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1989:192508 CAPLUS
DOCUMENT NUMBER: 110:192508
TITLE: Pteridines. Part LXXXVII. Synthesis and properties of 8-substituted 2-thiolumazines
AUTHOR(S): Huebsch, Walter; Pfleiderer, Wolfgang
CORPORATE SOURCE: Fak. Chem., Univ. Konstanz, Konstanz, D-7750, Fed. Rep. Ger.
SOURCE: Helvetica Chimica Acta (1988), 71(6), 1379-91
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:192508
GI



I

AB 2,8-Dihydro-2-thioxopteridin-(3H)-ones I (R = Me, CH2CH2OH, Ph; R1 = H, Me, Ph) and their S-Me derivs. have been synthesized by condensation of 5-amino-6-(substituted amino)-1,2-dihydro-2-thioxopyrimidin-4(3H)-ones and the S-Me derivs. with R1COCOR1. The presence of a quinonoid cross-conjugated .pi.-electron system makes this type of compd. susceptible to nucleophilic addns. in position 7, which leads to intramol. and intermol. covalent adducts.

IT **120270-33-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 120270-33-9 CAPLUS
CN Acetic acid, [(1,2,3,5,6,7-hexahydro-7-oxo-5-thioxoimidazo[1,2-c]pyrimidin-8-yl)amino]oxo- (9CI) (CA INDEX NAME)



L3 ANSWER 18 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1987:138142 CAPLUS
DOCUMENT NUMBER: 106:138142
TITLE: Anti-cyclization reactions of enantiomeric 1-(2,3-dihydroxypropyl)uracil derivatives
AUTHOR(S): Skaric, V.; Kasnar, B.
CORPORATE SOURCE: Lab. Stereochem. Nat. Prod., "Rudjer Boskovic" Inst., Zagreb, 41001, Yugoslavia
SOURCE: Croatica Chemica Acta (1986), Volume Date 1985, 58(4), 583-92
CODEN: CCACAA; ISSN: 0011-1643
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB 2-Hydroxymethyltetrahydrooxazolo[3,2-c]pyrimidine-5,7-(4H,6H)-diones (R,S)-I, (R)-I, and (S)-I (R = H) were prepd. The CH2N2 methylation of I (R = H) gave I (R = Me). For the synthesis of (R)- and (S)-I (R = H) (R)- and (S)-5-bromo-1-(2,3-dihydroxypropyl)uracil were treated with KCN in DMF. (R,S)-6-Cyano-1-(2,3-dihydroxypropyl)uracil underwent anti-cyclization yielding (R,S)-I (R = H) if heated in DMSO at 40.degree..

IT **107262-81-7P 107299-32-1P 107299-33-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and methylation of)

RN 107262-81-7 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 107299-32-1 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-, (R)- (9CI) (CA INDEX NAME)



RN 107299-33-2 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-, (S)- (9CI) (CA INDEX NAME)



IT **107262-90-8P 107299-35-4P 107380-09-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 107262-90-8 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 107299-35-4 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-6-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107380-09-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-6-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 19 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1985:6400 CAPLUS
DOCUMENT NUMBER: 102:6400
TITLE: kine-Substitution in a series of N-[.omega.-(5-bromouracil-1-yl)alkyl]alkylamines
AUTHOR(S): Lulle, I.; Paegle, R.; Lidaks, M.
CORPORATE SOURCE: Inst. Org. Sint., Riga, 226006, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1984), (9), 1260-1
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 102:6400
GI



AB kine-Substitution (sic) of title compds. I (R = Pr, Bu) with R1NH2 (R1 = Pr, Bu) gave 55-65% uracils II (R = R1 = Pr, Bu; R = Pr, R1 = Bu). Treating I (R = PhCH2) with R1NH2 gave an intramol. cyclized product III described earlier. A mechanism for these substitutions is discussed.
IT **86524-89-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 86524-89-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 20 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN

10/ 071,032

ACCESSION NUMBER: 1983:453697 CAPLUS
DOCUMENT NUMBER: 99:53697
TITLE: Synthesis of (1-uracilyl)alkylamines and their transformation into bicyclic systems
AUTHOR(S): Lulle, I.; Paegle, R.; Mazeika, I.; Lidaks, M.
CORPORATE SOURCE: Inst. Org. Sint., Riga, 226006, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1983), (4), 535-42
CODEN: KGSSAQ; ISSN: 0453-8234
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 99:53697
GI


I


II


III

AB Uracils I (R = H, Pr, Bu, PhCH2, X = H, n = 2, 3) were prepd. in 40-87% yields by amination of the corresponding bromides with RNH2. Bromination of I gave bromo derivs. I (X = Br, n = 2) which were cyclized in the presence of amines to give 40-60% II (R = H, Pr, Bu, PhCH2). Analogously obtained from I (X = Br, n = 3) were 40-55% III.

IT **21418-79-1P 86524-87-0P 86524-88-1P 86524-89-2P 86525-07-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 21418-79-1 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro- (8CI, 9CI) (CA INDEX NAME)



RN 86524-87-0 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-1-propyl- (9CI) (CA INDEX NAME)

10/ 071,032



RN 86524-88-1 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 1-butyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 86524-89-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 86525-07-7 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L3 ANSWER 21 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1983:137135 CAPLUS
DOCUMENT NUMBER: 98:137135

10/ 071,032

TITLE: Structure of a novel sulfur-containing metabolite of Acluracil (1-allyl-3,5-diethyl-6-chlorouracil)
AUTHOR(S): Kaul, R.; Hempel, B.; Kiefer, G.
CORPORATE SOURCE: Res. Lab., Pharm. Robugen G.m.b.H., Esslingen, D-7300, Fed. Rep. Ger.
SOURCE: Xenobiotica (1982), 12(8), 495-8
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB 6,8-diethyl-2-hydroxymethyltetrahydrothiazolo[3,2-c]pyrimidine-5,7(4H,6H)-dione (I) [**79831-08-6**] was identified as an Acluracil [20938-38-9] metabolite in rabbit urine by gas-liq. chromatog.-mass spectrometry. The mechanism of formation of this metabolite is discussed and a metabolic path for the formation of methylthio metabolites is proposed.

IT **79831-08-6**
RL: BIOL (Biological study)
(as Acluracil metabolite, structure of)

RN 79831-08-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 22 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:555876 CAPLUS
DOCUMENT NUMBER: 97:155876
TITLE: 2-14C-1-allyl-3,5-diethyl-6-chlorouracil. II: Isolation and structures of the major sulfur-free and three minor sulfur-containing metabolites and mechanism of biotransformation
AUTHOR(S): Kaul, Ravinder; Hempel, Bernd; Kiefer, Gebhard
CORPORATE SOURCE: Res. Lab., Pharm. Robugen G.m.b.H., Esslingen, D-7300, Fed. Rep. Ger.
SOURCE: Journal of Pharmaceutical Sciences (1982), 71(8), 897-900
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal

10/ 071,032

LANGUAGE: English

GI



I

AB The metabolites of 1-allyl-3,5-diethyl-6-chlorouracil (I) [20938-38-9] in rabbit urine were isolated by preparative thick-layer, liq.-column, and gas chromatog. With the aid of mass and 1H-NMR spectra, and by comparison with an authentic sample, the major metabolite was identified as 6,8-diethyl-2-(hydroxymethyl)-1-tetrahydrooxazolo[3,2-c]pyrimidine-5,7(4H,6H)-dione **[58137-53-4]**; the other metabolites were identified as 1-allyl-3-ethyl-5-(1-hydroxyethyl)-6-methylthiouracil [59453-66-6], 1-allyl-3,5-diethyl-6-methylthiouracil [59453-67-7], and 6,8-diethyl-2-(hydroxymethyl)tetrahydrothiazolo[3,2-c]pyrimidine-5,7(4H,6H)-dione **[79831-08-6]**. The mechanism of the formation of sulfur-contg. metabolites is discussed, and a new metabolic pathway for the formation of methylthio compds.. is proposed.

IT **58137-54-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetoxylation of)

RN 58137-54-5 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-6,8-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



IT **58137-53-4P 79831-08-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and formation of, as allyldiethylchlorouracil metabolite)

RN 58137-53-4 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 79831-08-6 CAPLUS

10/ 071,032

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 23 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:520029 CAPLUS
DOCUMENT NUMBER: 97:120029
TITLE: Identification of the major degradation product of 1-propyl-3,5-diethyl-6-chlorouracil in rabbits and mechanism of the formation of bicyclic barbituric acid metabolites
AUTHOR(S): Kaul, R.; Hempel, B.
CORPORATE SOURCE: Res. Lab., Pharm. Robugen G.m.b.H., Esslingen/Neckar, Fed. Rep. Ger.
SOURCE: Arzneimittel-Forschung (1982), 32(7), 722-3
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The major degrdn. product of antifungal 1-propyl-3,5-diethyl-6-chlorouracil (I) [52357-17-2] in rabbits was identified as 6,8-diethyl-2-methyl-tetrahydrooxazolo[3,2-c]pyrimidine-5,7-(4H,6H)-dione [**80557-14-8**]. The mechanism of the formation of this bicyclic barbituric acid deriv. is discussed. The biotransformation takes place via substitution of the chlorine by .beta.- and not by .alpha.-hydroxy group of the intermediate hydroxypropane.

IT **58137-54-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)

RN 58137-54-5 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-6,8-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



IT **80557-14-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of and as propyldiethylchlorouracil metabolite)
RN 80557-14-8 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 24 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:484667 CAPLUS
DOCUMENT NUMBER: 97:84667
TITLE: Identification of a third sulfur-containing metabolite of 1-allyl-3,5-diethyl-6-chlorouracil and mechanism of formation of methylthio-metabolites
AUTHOR(S): Kaul, R.; Kiefer, G.; Hempel, B.
CORPORATE SOURCE: Forschungslab., Firma Robugen G.m.b.H., Esslingen/Neckar, 7300, Fed. Rep. Ger.
SOURCE: Arzneimittel-Forschung (1982), 32(6), 610-12
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB A new S-contg. metabolite of 1-allyl-3,5-diethyl-6-chlorouracil (I) [20938-38-9] is reported. By comparison with a synthetic product, this metabolite was identified as 6,8-diethyl-2-hydroxymethyl-tetrahydrothiazolo[3,2-c]pyrimidine-5,7-(4H,6H)-dione (II) [

79831-08-6]. The mechanism of formation of II and other S-contg. metabolites of I in the rabbit is discussed.

IT **79831-08-6**
RL: BIOL (Biological study)
(as allyldiethylchlorouracil metabolite in urine)

RN 79831-08-6 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 25 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1982:143230 CAPLUS

DOCUMENT NUMBER: 96:143230

TITLE: Thio sugars. Part 7. Secouridines with amino groups in the carbohydrate component: intramolecular addition across the 5,6-double bond, and molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea residues

AUTHOR(S): McCormick, Joan E.; McElhinney, R. Stanley

CORPORATE SOURCE: Lab. Med. Res. Counc. Ireland, Dublin, 2, Ire.

SOURCE: Journal of Chemical Research, Synopses (1981), (10), 310-11
CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 96:143230

GI



IV



V

AB The prepn. of 5-halosecouridines with amino groups in the carbohydrate component from aminoalkyl sulfoxides and halouracils is described. E.g., Pummerer rearrangement of MeSO(CH2)2R (R = phthalimido) gave 37% of a 67:33 mixt. of MeSCHOAcCH2R (I) and R(CH2)2SCH2OAc. I underwent

condensation reaction with 5-fluorouracil in CH2Cl2 in the presence of SnCl4 to give MeSCHR1CH2R [R as before, R1 = 1-, 3-(5-fluorouracil)] (II and III, resp.) in 58 and 22% yields, resp. Dephthaloylation of II by H2NNH2 in MeO(CH2)2OH at 100.degree. for 1 h, followed by addn. reaction with Cl(CH2)2NCO in DMF at 1.degree. gave the bicyclic amide IV, which on isomerization by HBr/AcOH and nitrosation by NaNO2 in aq. HCl/CHCl3 gave the uridine V.

IT **81068-75-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and diazotization of)

RN 81068-75-9 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-(methylthio)- (9CI) (CA INDEX NAME)



IT **81068-77-1P 81068-95-3P 81138-81-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 81068-77-1 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 1-acetyl-2,3-dihydro-3-(methylthio)- (9CI) (CA INDEX NAME)



RN 81068-95-3 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-(methylthio)-8-nitroso- (9CI) (CA INDEX NAME)



RN 81138-81-0 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-(methylthio)-8-(phenylazo)- (9CI) (CA INDEX NAME)



L3 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:79362 CAPLUS
DOCUMENT NUMBER: 96:79362
TITLE: Structure of the major metabolite of 1-propyl-3,5-diethyl-6-chlorouracil in rabbits
AUTHOR(S): Kaul, R.; Hempel, B.
CORPORATE SOURCE: Res. Lab., Pharm. Robugen G.m.b.H., Esslingen, D-7300, Fed. Rep. Ger.
SOURCE: Chemosphere (1981), 10(10), 1181-4
CODEN: CMSHAF; ISSN: 0045-6535
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB The major metabolite of 1-propyl-3,5-diethyl-6-chlorouracil (I) [52357-17-2] was identified as 6,8-diethyl-2-methyl-tetrahydrooxazolo[3,2-c]pyrimidine-5,7(4H,6H)-dione (II) [**80557-14-8**]. The biotransformation to this bicyclic barbituric acid deriv. takes place via substitution of the chlorine by .beta.- and not by .alpha.-hydroxy group of the intermediate hydroxypropane.

IT **80557-14-8**
RL: BIOL (Biological study)
(as propyldiethylchlorouracil metabolite)

RN 80557-14-8 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 27 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1982:196 CAPLUS
DOCUMENT NUMBER: 96:196
TITLE: Mechanism of formation of methylthio metabolites investigated on the biotransformation of 1-allyl-3,5-diethyl-6-chlorouracil in rabbits
AUTHOR(S): Kaul, R.; Kiefer, G.; Hempel, B.
CORPORATE SOURCE: Res. Lab., Pharm. Robugen G.m.b.H., Esslingen, D-7300, Fed. Rep. Ger.
SOURCE: Chemosphere (1981), 10(8), 929-34
CODEN: CMSHAF; ISSN: 0045-6535
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A new S-contg. metabolite of 1-allyl-3,5-diethyl-6-chlorouracil (I) [20938-38-9] is reported. By comparison with an authentic sample (synthesis described), this metabolite was identified as 6,8-diethyl-2-(hydroxymethyl)tetrahydrothiazolo[3,2-c]pyrimidine-5,7(4H,6H)-dione **[79831-08-6]**. The mechanism of formation of S-contg. metabolites is discussed.

IT **79831-08-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and formation of, as allylchlorouracil metabolite)

RN 79831-08-6 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 28 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:407200 CAPLUS
DOCUMENT NUMBER: 95:7200
TITLE: Reaction of 3-dimethylamino-2,2-dimethyl-2H-azirine with barbituric acid
AUTHOR(S): Link, Helmut; Bernauer, Karl; Daly, John J.; Chaloupka, Stanislav; Heimgartner, Heinz
CORPORATE SOURCE: Pharm. Forschungasbt., F. Hoffmann-La Roche und Co. A.-G., Basel, CH-4002, Switz.
SOURCE: Helvetica Chimica Acta (1981), 64(1), 49-63

10/ 071,032

CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I



II

AB The reaction of 3-dimethylamino-2,2-dimethyl-2H-azirine with barbituric acid in DMF at room temp. yields a mixt. of several compds. The main products I and II were isolated in 40 and 10% yield, resp., and their structures established by x-ray anal. Reaction mechanisms for the formation of I and II are postulated, the first step being either a C- or an N-alkylation of barbituric acid. Redn. of I and II with NaBH4 in EtOH at room temp. yields 6,6-dimethyl-1,5,6,7-tetrahydropyrrolo[2,3-d]pyrimidine-2,4(3H)-dione and 3,3-dimethyl-2,3-dihydroimidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione in 38 and 48% yield, resp. Treatment of II with 3 N aq. NaOH at room temp. gives 51% 3,3-dimethyl-imidazo[1,2-c]pyrimidine-2,5,7(1H,3H,6H)-trione.

IT **77864-11-0P 77864-12-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 77864-11-0 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 77864-12-1 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2,5,7(1H,3H,6H)-trione, 3,3-dimethyl- (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:175055 CAPLUS
DOCUMENT NUMBER: 94:175055

10/ 071,032

TITLE: Pteridines. LXX. Synthesis and properties of 1,8-alkylene-bridged lumazines

AUTHOR(S): Uhlmann, Eugen; Pfleiderer, Wolfgang
CORPORATE SOURCE: Fak. Chem., Univ. Konstanz, Konstanz, D-7750, Fed. Rep. Ger.

SOURCE: Heterocycles (1981), 15(1), 437-53
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



I II

AB The lumazines I (n = 1, 2) and II (R = Me, R1 = H, R2R3 = CH2, n = 1, 2; R = R1 = Me, R2R3 = CH2, n = 1; R = R2 = Ph, R1 = H, R3 = OH, n = 1, 2) were prepd. to det. the protonation site in lumazine. UV spectra indicate a mixt. of .gtoreq.2 cationic species.

IT **77178-56-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with diacetyl)
RN 77178-56-4 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 8-amino-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



IT **77178-51-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with glyoxal)
RN 77178-51-9 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 8-amino-2,3-dihydro- (9CI) (CA INDEX NAME)



IT **77178-47-3P 77178-48-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)
RN 77178-47-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-8-nitro- (9CI) (CA INDEX NAME)



RN 77178-48-4 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-6-methyl-8-nitro- (9CI) (CA INDEX NAME)



L3 ANSWER 30 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1981:121439 CAPLUS
DOCUMENT NUMBER: 94:121439
TITLE: 5-Aryl-7-(N-arylcarbamoyl)-4,6-dioxo-2,3,3a,4,5,6-hexahydrooxa(thia)zolo[2,3-c]pyrimidines and 3-(N-arylcarbamoyl)-2,4-dihydroxyquinolines from 2-methyloxa(thia)zoline and aryl isocyanates
AUTHOR(S): Richter, R.; Ulrich, H.
CORPORATE SOURCE: D. S. Gilmore Res. Lab., Upjohn Co., North Haven, CT, 06473, USA
SOURCE: Journal of Organic Chemistry (1979), 44(26), 4877-80
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:121439
AB Two structurally different heterocyclic products, 5-aryl-7-(N-arylcarbamoyl)-4,6-dioxo-2,3,3a,4,5,6-hexahydrooxazolo- and

-thiazolo[2,3-c]pyrimidines and 3-(N-arylcarbamoyl)-2,3-dihydroxyquinolines are obtained in low yield on heating 2-methyloxazoline or 2-methylthiazoline with aryl isocyanates to .apprx.150.degree.. The structures of both heterocyclic products were confirmed.

IT **71901-57-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and ring cleavage of)

RN 71901-57-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-8-carboxamide, 2,3,6,7-tetrahydro-5,7-dioxo-N,6-diphenyl- (9CI) (CA INDEX NAME)



IT **71886-04-9P 71886-05-0P 71886-06-1P 71886-07-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 71886-04-9 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-8-carboxamide, 2,3,6,7-tetrahydro-N,6-bis(4-methylphenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 71886-05-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxamide, 2,3,6,7-tetrahydro-5,7-dioxo-N,6-diphenyl- (9CI) (CA INDEX NAME)

10/ 071,032



RN 71886-06-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxamide, 2,3,6,7-tetrahydro-N,6-bis(4-methylphenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 71886-07-2 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-8-carboxamide, 2,3,6,7-tetrahydro-N,6-bis(3-methylphenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 31 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1980:471704 CAPLUS
DOCUMENT NUMBER: 93:71704
TITLE: Transformation of .beta.-(5-bromouracil-1-yl)-.alpha.-

10/ 071,032

alanine into imidazo[1,2-c]pyrimidine

AUTHOR(S): Paegle, R.; Lulle, I.; Krisane, V.; Mazeika, I.; Liepins, E.; Lidaks, M.

CORPORATE SOURCE: Inst. Org. Sint., Riga, 226006, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1980), (4), 538-40
CODEN: KGSSAQ; ISSN: 0453-8234

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI



I

AB The title transformation to imidazopyrimidinecarboxylate I (R = H) (II) took place in 89-90% yield by heating the uracil alanine deriv. with a secondary amine, e.g., MeCHEtNH2, PhCH2NH2, cyclopentylamine, morpholine, or piperidine. II was easily brominated in the 8 position to give 76.1% I (R = Br).

IT **74376-84-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and bromination of)

RN 74376-84-4 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 1,2,3,5,6,7-hexahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



IT **74376-85-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 74376-85-5 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 8-bromo-1,2,3,5,6,7-hexahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 32 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1978:50914 CAPLUS
DOCUMENT NUMBER: 88:50914
TITLE: Fused pyrimidine derivatives
INVENTOR(S): Furukawa, Sumiyasu; Shima, Shunsuke
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52128393	A2	19771027	JP 1976-45735	19760421

PRIORITY APPLN. INFO.: JP 1976-45735 19760421
GI For diagram(s), see printed CA Issue.
AB Fifteen I (R = H or alkyl, R1 = alkyl, Ph, etc., Z = O or S, n = 2 or 3), useful as antiinflammatory and diuretic drugs (no data), were prepd. by treating II with R1CNZ. Thus, 1.7 g II (R = H, n = 2) and MeCNS in DMF were stirred 16 h at 140-50.degree. to give 950 mg I (R = H, R1 = Me, Z = S, n = 2).
IT **65315-48-2P 65315-49-3P 65315-50-6P**
65315-51-7P 65315-52-8P 65315-53-9P
65315-54-0P 65315-55-1P 65315-56-2P
65315-57-3P 65315-58-4P 65315-59-5P
65315-60-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 65315-48-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 1,2,3,5,6,7-hexahydro-N-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-49-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 1,2,3,5,6,7-hexahydro-N-(4-hydroxyphenyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-50-6 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, N-(4-chlorophenyl)-1,2,3,5,6,7-hexahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-51-7 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 6-ethyl-1,2,3,5,6,7-hexahydro-5,7-dioxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 65315-52-8 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 6-ethyl-1,2,3,5,6,7-hexahydro-N-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-53-9 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 6-ethyl-1,2,3,5,6,7-hexahydro-5,7-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 65315-54-0 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 1,2,3,5,6,7-hexahydro-5,7-dioxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 65315-55-1 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, N-ethyl-1,2,3,5,6,7-hexahydro-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-56-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, 1,2,3,5,6,7-hexahydro-N-(2-methylpropyl)-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-57-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carboxamide, N-(4-chlorophenyl)-1,2,3,5,6,7-hexahydro-6-methyl-5,7-dioxo- (9CI) (CA INDEX NAME)



RN 65315-58-4 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 6-ethyl-1,2,3,5,6,7-hexahydro-5,7-dioxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 65315-59-5 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carbothioamide, N-cyclohexyl-6-ethyl-1,2,3,5,6,7-hexahydro-5,7-dioxo- (9CI) (CA INDEX NAME)

10/ 071,032



RN 65315-60-8 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 1,2,3,5,6,7-hexahydro-5,7-dioxo-N-phenyl- (9CI) (CA INDEX NAME)



L3 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1976:17269 CAPLUS
DOCUMENT NUMBER: 84:17269
TITLE: Structure of the major metabolite of 1-allyl-3,5-diethyl-6-chlorouracil. New bicyclic barbituric acid derivatives
AUTHOR(S): Fischer, P.; Kaul, R.; Kiefer, G.; Erhardt, S.; Hempel, B.
CORPORATE SOURCE: Inst. Org. Chem., Univ. Stuttgart, Stuttgart, Fed. Rep. Ger.
SOURCE: Tetrahedron Letters (1975), (41), 3521-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The structure of the major metabolite (70-80%), extd. from rabbit urine, of the title compd. was detd. as the oxazolopyrimidine I from chem. and spectral data.
IT **30345-99-4 58137-54-5 58137-55-6**
RL: PRP (Properties)
(NMR spectrum of)
RN 30345-99-4 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-2,3-dihydro-8-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 58137-54-5 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-6,8-diethyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 58137-55-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



IT **58137-53-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(uracil deriv. metabolite, mol. structure of)
RN 58137-53-4 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6,8-diethyl-2,3-dihydro-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 34 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:140163 CAPLUS
DOCUMENT NUMBER: 82:140163

10/ 071,032

TITLE: 2,3,5,7-Tetrahydro-2,2-dimethyl-5,7-dioxo-8-hydronitrogeno-5H-thiazolo[3,2-c]pyrimidine-3-carboxylic acids, esters and alkali metal salts
INVENTOR(S): Nudelman, Abraham; Cynwyd, Bala; McCaully, Ronald J.
PATENT ASSIGNEE(S): American Home Products Corp.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3850933	A	19741126	US 1973-345803	19730328

PRIORITY APPLN. INFO.: US 1973-345803 19730328

GI For diagram(s), see printed CA Issue.

AB Ring enlargement of penicillanates I (R1 = PhOCH2CO, PhCH2CO; R2 = CH2C6H4NO2-p, CH2C6H4Me-p) with EtO2CNCO gave antitrichomonal II. Thus, refluxing I R1 = PhOCH2CO, R2 = CH2C6H4NO2-p) with EtO2CNCO in THF gave 54% II (same R1, R2), which was refluxed in HCl-MeO to give 65% II (R1 = H, R2 = CH2C6H4NO2-p) (III). III gave 99% kill of Trichomonas vaginalis at 1000 .mu.g/ml.

IT **54820-45-0P 54820-48-3P 54820-49-4P 54820-50-7P 54820-51-8P 54820-52-9P 54820-53-0P 54820-54-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(antitrichomonal, prepn. of)

RN 54820-45-0 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-8-[(phenoxyacetyl)amino]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 54820-48-3 CAPLUS

CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-8-[(phenoxyacetyl)amino]- (9CI) (CA INDEX NAME)



10/ 071,032

RN 54820-49-4 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 8-amino-2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 54820-50-7 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-8-[(phenylacetyl)amino]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



RN 54820-51-8 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-8-[(phenylacetyl)amino]- (9CI) (CA INDEX NAME)



RN 54820-52-9 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-8-[(phenoxyacetyl)amino]-, (4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 54820-53-0 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 8-amino-2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo-, (4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 54820-54-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-3-carboxylic acid, 8-amino-2,3,6,7-tetrahydro-2,2-dimethyl-5,7-dioxo- (9CI) (CA INDEX NAME)



L3 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:111360 CAPLUS
DOCUMENT NUMBER: 78:111360
TITLE: Uracil derivatives
INVENTOR(S): Ley, Kurt; Aichinger, Gerd; Botta, Arthur; Hagemann, Hermann; Niemers, Ekkehard
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2126148	A	19721207	DE 1971-2126148	19710526

PRIORITY APPLN. INFO.: DE 1971-2126148 19710526

10/ 071,032

GI For diagram(s), see printed CA Issue.
AB Thirty-nine uracil derivs. of the general formula I, e.g. I [R = OCH2Ph, morpholino; R1 = Ph, Cl, OMe; R2 = H; RR2 = (CH2)10], II (n = 2, 4; m = 2, 3), or III, were prepd. by reaction of R2CH2C(:NR)R1 with XCONCO (X = Cl, PhO) or (EtO2C)2NH and were useful as plant protective agents. Thus, melting 1,8-diazabicyclo[5.3.0]dec-7-ene and (EtO2C)2NH and distn. of EtOH gave 62.9% II (n = 4, m = 2).
IT **40721-30-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 40721-30-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 36 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:16119 CAPLUS
DOCUMENT NUMBER: 78:16119
TITLE: Acyl and thioacyl isocyanates. XI. Reactions of benzoyl and thiobenzoyl isocyanates with 2-thiazolines and 2-oxazolines
AUTHOR(S): Tsuge, O.; Kanemasa, S.
CORPORATE SOURCE: Res. Inst. Ind. Sci., Kyushu Univ., Fukuoka, Japan
SOURCE: Tetrahedron (1972), 28(18), 4737-46
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 78:16119
GI For diagram(s), see printed CA Issue.
AB PhCSNCO reacted with 2-thiazoline and 2-methyl-2-thiazoline (I) to give 6,7-dihydro-2-phenylthiazolo-[2,3,-b]-1,3,5-thiadiazin-4(8aH)-one (II) and its 8a-Me deriv., resp. BzNCO reacted with I to give 2,3-dihydro-5-phenyl-8-(benzoylcarbamoyl)thiazolo[3,2-c]pyrimidin-7-one (III); PhCSNCO reacted with I and 2-methyl-2-oxazoline (IV) at 90.degree. to give the corresponding 8-[(thiobenzoyl)carbanoyl]thiazolo- and -oxazolo[3,2-c]pyrimidin-7-ones, while reaction of BzNCO with IV gave 2-[bis(benzoylcarbamoyl)methylene]oxazolidine which, with AcOH, gave the corresponding oxazolo[3,2-c]pyrimidine. BzNCO reacted with 2-ethyl-2-thiazoline to give 2,3-dihydro-6-benzoyl-8-methylthiazolo[3,2-c]pyrimidine-5,7-dione and 2,3-dihydro-5-phenyl-8-methylthiazolo[3,2-c]pyrimidin-7-one. The reactions proceed by attack of the isocyanates on the tautomeric enamines of 2-alkyl-2-thiazoline and-2-oxazoline.
IT **39931-56-1P 39931-58-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 39931-56-1 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 6-benzoyl-2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)

10/ 071,032



RN 39931-58-3 CAPLUS
CN 5H-Thiazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-methyl- (9CI) (CA INDEX NAME)



L3 ANSWER 37 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:153717 CAPLUS
DOCUMENT NUMBER: 76:153717
TITLE: Biosynthesis of pteridines. VI. Mechanism of riboflavine biosynthesis
AUTHOR(S): Paterson, Thomas; Wood, H. C. S.
CORPORATE SOURCE: Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1972), (8), 1051-6
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB D exchange of the Me protons in the lumazine precursor 6,7-di-methyl-8-D-ribityl-2,4-pteridinedione (I) of riboflavine and ir related compds., e.g. 8-(2-hydroxyethyl)-6,7-dimethyl-2,4-pteri-dinedione (II), was studied by NMR. The 7-Me protons in I exchanged with the solvent, but those of the 6-Me group did not; a highly delocalized anionic intermediate was suggested. Re-fluxing D-labeled II in D2O at pH 7.3 gave 9-(2-hydroxyethyl)-6,7-dimethylisoalloxazine (III). A mechanism was proposed which explained the distribution of the D label in III and which may be related to the enzymic synthesis of riboflavine.
IT **36252-29-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 36252-29-6 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-2,2,3-trimethyl-8-nitro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1971:510266 CAPLUS
DOCUMENT NUMBER: 75:110266
TITLE: Synthesis of bicyclo[4.3.0]nonanebarbituric and thiobarbituric acid derivatives and a bicyclo[4.4.0]decanebarbituric acid derivative
AUTHOR(S): Smissman, Edward E.; Ayres, James W.
CORPORATE SOURCE: Sch. Pharm., Univ. Kansas, Lawrence, KS, USA
SOURCE: Journal of Organic Chemistry (1971), 36(17), 2407-9
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In attempting to prep. intramol. C-alkylated bicyclic barbituric and thiobarbituric acids from N-haloalkylbarbituric and N-haloalkylthiobarbituric acids, only O-alkylated compds. were obtained. The structures were assigned on the basis of spectral data and by degradation of the products to known entities.

IT **30345-98-3P 30345-99-4P 30346-00-0P 30346-01-1P 30346-02-2P 30346-03-3P 30346-04-4P 30346-05-5P 30346-06-6P 30409-27-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 30345-98-3 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-methyl-8-phenyl- (8CI) (CA INDEX NAME)



RN 30345-99-4 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-2,3-dihydro-8-phenyl- (8CI, 9CI) (CA INDEX NAME)



RN 30346-00-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-8-phenyl-, acetate (ester) (8CI) (CA INDEX NAME)



RN 30346-01-1 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-8-phenyl-, benzoate (ester) (8CI) (CA INDEX NAME)



RN 30346-02-2 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(iodomethyl)-8-phenyl- (8CI) (CA INDEX NAME)



RN 30346-03-3 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-methyl-8-phenyl-5-thio- (8CI) (CA INDEX NAME)



RN 30346-04-4 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-(hydroxymethyl)-8-phenyl-5-thio-, acetate (ester) (8CI) (CA INDEX NAME)



RN 30346-05-5 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-2-methylene-8-phenyl-5-thio- (8CI) (CA INDEX NAME)



RN 30346-06-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-8-phenyl- (8CI) (CA INDEX NAME)



RN 30409-27-9 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-(bromomethyl)-2,3-dihydro-8-phenyl-5-thio- (8CI) (CA INDEX NAME)

10/ 071,032



L3 ANSWER 39 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1969:68296 CAPLUS
DOCUMENT NUMBER: 70:68296
TITLE: 2-Hydroxymethyl-2-imidazolines and 2-imidazoline-2-acetic acids. II. Actual structure of 2-imidazoline-2-acetic acids
AUTHOR(S): Cardellini, Mario; Liberatore, Felice; Morlacchi, Flaviano
CORPORATE SOURCE: Ist. Chim. Farm., Univ. Bari, Bari, Italy
SOURCE: Annali di Chimica (Rome, Italy) (1968), 58(11), 1199-205
CODEN: ANCRAI; ISSN: 0003-4592
DOCUMENT TYPE: Journal
LANGUAGE: Italian

AB Some imidazolineacetic esters were prepd. and shown from ir, uv, and N.M.R. spectral data to be derivs. of 2-imidazolidylideneacetic acid. Ethyl .beta.-imino-.beta.-ethoxypropionate-HCl (63 g.), was added slowly to a soln. of 19.5 g. ethylenediamine in 300 cc. EtOH at 0.degree.. The mixt. was refluxed for 25-30 hrs. and filtered to remove the white ppt. formed. The soln. was cooled to 0.degree., and a soln. of NaOEt (6.5 g. Na in 200 cc. EtOH) was added slowly with stirring. The solvent was removed in vacuo to give 45 g. Et 2-imidazolidinyli-deneacetate (I), m. 115-17.degree.; picrate m. 144-6.degree.. I (1.5 g.) was stirred in 100 cc. C6H6 at room temp. and 1.15 g. of PhNCO was added to give 2.4 g. Et 1-(phenylcarbamoyl)-2-imidazoline-2-acetate (II), m. 100-10.degree.. II (1.8 g.) was refluxed 1 hr. in 50 cc. EtOH to give 1.1 g. 1,2,3,5,6,7-hexahydro-6-phenylimidazo-[1,2-c]pyrimidine-5,7-dione, m. 284-6.degree.. II (0.5 g.) was refluxed 2 hrs. in 30 cc. C6H6 or PhMe to give 0.5 g. Et .alpha.-(phenylcarbamoyl)-2-imidazolidinylideneacetate, m. 123-5.degree.. I (1 g.) was dissolved in 60 cc. C6H6 and treated with 1.7 g. PhNCO for 12 hrs. at room temp. to give 2 g. Et .alpha.,1-bis(phenylcarbamoyl)-2-imida-zolidinylideneacetate (III), m. 130-40.degree.. III (0.4 g.) was refluxed in 30 cc. EtOH for 2 hrs. to give 1,2,3,5 6,7-hexahydro-6-phenyl-8-(phenylcarbamoyl)imidazo[1,2-c]pyrimidine-5,7-dione, m. 292-3.degree.. I (2 g.) was dissolved in 13.7 cc. N H2SO4 and stirred with an aq. soln. of 1 g. KOCN. The H2O was removed in vacuo at room temp. and the solid obtained extd. with boiling EtOH. The ext. gave 1.4 g. residue of Et .alpha.-carbamoyl-2-imidazolidinylidene-acetate, m. 165-8.degree.. The remaining solid was washed in boiling EtOH to give 1,2,3,5,6,7-hexahydroimidazo[1,2-c]pyrimidine-5,7-dione, m. 345.degree. (H2O). The spectra of the derivs. suggested the enamine structure.

IT **21418-74-6P 21418-77-9P 21418-79-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 21418-74-6 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-6-phenyl- (8CI) (CA INDEX NAME)



RN 21418-77-9 CAPLUS
CN Imidazo[1,2-c]pyrimidine-8-carboxamide, 1,2,3,5,6,7-hexahydro-5,7-dioxo-N,6-diphenyl- (9CI) (CA INDEX NAME)



RN 21418-79-1 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro- (8CI, 9CI) (CA INDEX NAME)



L3 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1969:20289 CAPLUS
DOCUMENT NUMBER: 70:20289
TITLE: Pteridines. XXXVI. Reaction of 4-chloro-5-nitropyrimidines and glucosamine
AUTHOR(S): Pfleiderer, Wolfgang; Buehler, Eberhard; Schmidt, Dieter
CORPORATE SOURCE: Univ. Stuttgart, Stuttgart, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1968), 101(11), 3794-801
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 70:20289
GI For diagram(s), see printed CA Issue.
AB 2-Amino-2-deoxy-D-glucopyranose (I) reacted with II (R = H or Me) and 4-chloro-2-dimethylamino-5-nitropyrimidine to give the corresponding 4-(2-arylamino-2-deoxy-D-glucose) compds. Treatment of I with III gave corresponding deriv., which cyclized to D-arabino-IV. 2-Deoxy-(1,3-dimethyl-5-nitrouracil-4-ylamino)-D-glucose was obtained under mild conditions from 4-chloro-1,3-dimethyl-5-nitrouracil and 2 equivs. I. It underwent spontaneous hydrolysis to 1,3-dimethyldilituric

acid. Raney Ni redn. of 2-(2-amino-1-methyl-5-nitro-6-oxodihydropyrimidin-4-ylamino)-2-deoxy-D-glucose gave 2-amino-8,9-dihydroxy-7-hydroxymethyl-4-oxo-3-methyloctahydro-7H-pyrano[2,3-g]pteridine.

IT **22090-68-2P 22090-69-3P 22169-68-2P 22169-69-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 22090-68-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxaldehyde, 1,2,3,5,6,7-hexahydro-3-hydroxy-8-nitro-5,7-dioxo- (8CI) (CA INDEX NAME)



RN 22090-69-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-2-carboxaldehyde, 1,2,3,5,6,7-hexahydro-3-hydroxy-6-methyl-8-nitro-5,7-dioxo- (8CI) (CA INDEX NAME)



RN 22169-68-2 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-8-nitro-2-(D-arabino-1,2,3,4-tetrahydroxybutyl)- (8CI) (CA INDEX NAME)



RN 22169-69-3 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-6-methyl-8-nitro-2-(D-arabino-1,2,3,4-tetrahydroxybutyl)- (8CI) (CA INDEX NAME)

10/ 071,032



L3 ANSWER 41 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:490644 CAPLUS
DOCUMENT NUMBER: 65:90644
ORIGINAL REFERENCE NO.: 65:16964g-h,16965a-h,16966a-b
TITLE: Pyrimidines series. XVII. Synthesis of imidazo[1,2-c]pyrimidines and 4-imidazolines
AUTHOR(S): Zondler, Helmut; Pfleiderer, Wolfgang
CORPORATE SOURCE: Tech. Hochsch., Stuttgart, Germany
SOURCE: Chemische Berichte (1966), 99(9), 2984-96
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 65:90644
GI For diagram(s), see printed CA Issue.
AB cf. CA 61, 16340c; 63, 8470c. Treating 4-chloro-5-nitropyrimidines (I) with aminoacetal and its alkyl derivs. yielded after acid hydrolysis of the products in general not the free aldehydes but by cyclization with the N-3 atom the corresponding imidazo[1,2-c]pyrimidines or by a secondary reaction the corresponding 4-imidazolines (II). The structure detns. of the reaction products are based on their pK values and uv spectra. I (R = R' = H) (III) (1.9 g.) in 4 cc. HCONMe2 treated with 3 cc. MeNHCH2CH(OEt)2 (IV) yielded 2.2 g. yellow V (R = R' = H, R'' = Me) (VI), m. 178-9.degree., resolidifying and remelting at about 260.degree. (decompn.). I (R = H, R' = Me) (VII) (2.05 g.) in 15 cc. EtOH and 3 cc. IV refluxed 5 min. gave 1.85 g. yellow V (R = H, R' = R'' = Me) (VIII), m. 77-9.degree.. III (1 g.) in 5 cc. EtOH refluxed 3 min. with 3 cc. PhCH2NHCH2CH(OEt)2 gave 0.93 g. yellow V (R = R' = H, R'' = PhCH2) (IX), m. 265.degree. (when placed on the block at 195.degree., m. 204-5.degree., resolidifying and remelting at 265.degree.). VII (1 g.) in 5 cc. EtOH refluxed 5 min. with 1.5 cc. H2NCH2CH(OEt)2 (X) yielded 0.73 g. V (R = R'' = H, R' = Me) (XI), m. 140-1.degree.. V (R = R' = R'' = H) (XII) (1 g.) in 60 cc. 0.5N NaOH treated with 20 cc. concd. HCl gave 0.68g. XIII (R = R' = R'' = H) (XIV), m. from 200.degree. (decompn.). XII (1 g.) and 30 cc. N HCl refluxed 0.5 hr. yielded 0.43 g. (XII). HCl m. from 200.degree. (decompn.). XII (1.4 g.) in 30 cc. 50% H2SO4 refluxed 15 min. and dild. with 110 cc. H2O gave 1 g. XII.H2O.0.5H2SO4, m. 227-30.degree. (decompn.) (placed on the block at 220.degree.). XI (0.6 g.) and 5 cc. N HCl refluxed 1 min. and refrigerated overnight gave 0.45 g. XIII (R = R'' = H, R' = Me) (XV), m. >300.degree.. VI (5 g.) in 60 cc. cold N NaOH treated with cooling with 30 cc. HCl, kept 24 hrs., and neutralized with solid NaHCO3, and the crude product boiled with 10 cc. AcOH in 350 cc. H2O yielded 1.8 g. yellow XVI, m. 266.degree. (decompn.). VI (0.5 g.) in 2 cc. Ph2O refluxed 1 min. gave 0.2 g. XVI. XVI (2.1 g.) in 100 cc. MeOH hydrogenated over Raney Ni gave 0.5 g. light yellow XVII, m. 255-7.degree. (decompn.) [m. 267-8.degree. (decompn.) when placed at 250.degree. on the block]. VI (2.2 g.) in 100 cc. MeOH hydrogenated over Raney Ni, and the light brownish ppt. treated 2 days at room temp. with 20 cc. 2N HCl and neutralized with NaHCO3 gave 0.97 g. (crude) XVII, m. 254.degree. (decompn.). VI (1 g.) refluxed 20 min. with 15 cc. N HCl gave 0.35 g. orange-red II (R = R' = H, R'' = Me) (XVIII), m. 231.degree. (decompn.) (H2O). XVII (1.2 g.) and 15 cc. N HCl gave similarly 0.59 g. XVIII. VIII

(1.35 g.) refluxed 0.5 hr. with 15 cc. N HCl yielded 0.38 g. orange-red II (R = R'' = Me, R' = H), m. 146-7.degree.. V(R = R" = Me, R' = H) (XIX) (1.5 g.) in 20 cc. 2N HCl refluxed 45 min. and adjusted with solid NaHCO3 to pH 8 yielded 0.57 g. orange-red II (R = R' = R' = Me) (XX), m. 182.degree. (H2O). IX (1.26 g.), 20 cc. H2O, 5 cc. concd. HCl, and a few drops C8H17OH refluxed 45 min. gave 0.1 g. orange-red II (R = R' = H, R' = PhCH2), m. 164.degree. (EtOH). XX (12.5 g.) in 70 cc. HCONMe2 treated with 17 cc. IV, concd. after several hrs. to 25.degree., and refrigerated overnight yielded 5.23 g. (crude) XXI, m. 210.degree. (EtOH). 4-Chloro-5-nitrouracil (XXII) (1.85 g.) 10 cc. EtOH, and 3 cc. X in 80 cc. EtOH refluxed to soln. and kept overnight yielded 1.28 g. XXIII (R = H) (XXIV), m. 263-5.degree. (decompn.) (EtOH) [when placed on the block, m. 183.degree. resolidifying and remelting at 263-5.degree.]. XXII (1.75 g.) in 10 cc. EtOH with 3 cc. IV yielded 1.25 g. yellow IV salt of XXIII (R = Me) (XXV), m. 141.degree. (EtOH). XXIV (0.3 g.) in 6 cc. 2N HCl heated briefly gave 0.15 g. XXVI (R = R' = H) (XXVII), m. 270-80.degree. (decompn.) [m. 277.degree. (decompn.) when placed on the block at 270.degree.]. IV salt (1.12 g.) of XXV refluxed 15 min. with 10 cc. N HCl gave 0.1 g. yellow XXVI (R = Me, R' = H) (XXVIII), m. 211-12.degree. (decompn.) (EtOH). IV salt (0.45 g.) of XXV in 2 cc. C8H17OH refluxed a few min. yielded 0.07 g. yellow XXVI (R = Me, R' = Et) (XXIX), m. 236-7.degree. (decompn.) (EtOH). VIII (1.05 g.) in 25 cc. 2N HCl kept 0.5 hr. at room temp. and neutralized with NaHCO3 gave 0.11 g. yellow XXX, m. 143-5.degree. (CHCl3-CCl4). 5-Nitroso-2,4-diamino-3-methylpyrimidine (5 g.) in 70 cc. CF3CO2H treated dropwise with starting at room temp. during 4 hrs. with 9 cc. 30% H2O2 and stirred 2 hrs. gave 2.7 g. light yellowish 5-nitro-2,4-diamino-6-oxo-3-methyldihydropyrimidine (XXXI), m. 262.degree. (decompn.) (H2O). 4-Methylaminouracil (XXXII) (5 g.) in 10 cc. concd. H2SO4 treated dropwise at 0.degree. with stirring with 5 cc. fuming HNO3 (d. 1.5) kept 15 min., and poured onto ice gave 4 g. 5-NO2 deriv. (XXXIII) of XXXII, m. >310.degree. (decompn.) (H2O). 4-Methylamino-3-methyluracil (XXXIV) (3 g.) in 6 cc. concd. H2SO4 with 3 cc. HNO3 (d. 1.5) gave similarly 2.4 g. 5-NO2 deriv. (XXXV) of XXXIV, m. 260.degree. with foaming (H2O). XXII (2 g.) and 10 c. 40% aq. Me2NH heated 5 min. on the water bath gave 1.2 g. yellow 4-Me2N analog XXXVI of XXII, m. 247.degree. (decompn.) The pK values in H2O at 20.degree. given were detd. for the following compds.: 2-amino-4-methylamino-5-nitro-6-oxodihydropyrimidine (XXXVII), -0.37 .+-. 0.03, 8.70 .+-. 0.1; XII, 0.58 .+-. 0.02, 8.99 .+-. 0.06; XIV, 2.34 .+-. 0.02, 8.50 .+-. 0.03; 1-Me deriv. of XXXVII, -0.17 .+-. 0.12; XI, 0.88 .+-. 0.04, 12.75 .+-. 0.05; XV, 2.45 .+-. 0.05; 2-amino-4-dimethylamino-5-nitro-6-oxodihydropyrimidine (XXXVIII), -0.62 .+-. 0.15, 8.53 .+-. 0.07; VI, 0.73 .+-. 0.06, 8.21 .+-. 0.1; XVII, 2.25 .+-. 0.02; 1-Me deriv. of XXXVIII, -0.36 .+-. 0.1; 2,4-bis(dimethylamino)-5-nitro-6-oxodihydropyrimidine, -1.59 .+-. 0.07, 8.52 .+-. 0.05; XIX, 0.60 .+-. 0.04, 8.29 .+-. 0.07; XXX, 4.91 .+-. 0.01; XXXI, 2.80 .+-. 0.09; XXXIII, 5.11 .+-. 0.04, 13.23 .+-. 0.1; 1-Me deriv. (XXXIX) of XXXIII, 5.29 .+-. 0.04; XXIV, 4.45 .+-. 0.06, 12.98 .+-. 0.05; XXXV, 8.50 .+-. 0.02; 11.97 .+-. 0.1; XXVII, 8.49 .+-. 0.01; XXXVI, 4.84 .+-. 0.03, 13.11 .+-. 0.04; 1-Me deriv. (XL) of XXXVI, 4.96 .+-. 0.03; XXV, 4.48 .+-. 0.06, 12.78 .+-. 0.07; XXVIII, 8.44 .+-. 0.05; XXIX, 8.11 .+-. 0.06. The uv max. and extinction coeff. of the same compds. and of VIII at various pH values are tabulated. The uv spectra of XI, XV, XVII, XXIV, XXV, XXVII, XXVIII, XXIX, XXX, XXXIX, and XL are recorded.

IT **7637-50-5**, Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-8-nitro- **7637-51-6**, Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-1-methyl-8-nitro- **7637-52-7**, Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 3-ethoxy-2,3-dihydro-1-methyl-8-nitro-
(prepn. of)

RN 7637-50-5 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-8-nitro- (7CI, 8CI) (CA INDEX NAME)



RN 7637-51-6 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-3-hydroxy-1-methyl-8-nitro- (7CI, 9CI) (CA INDEX NAME)



RN 7637-52-7 CAPLUS
CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 3-ethoxy-2,3-dihydro-1-methyl-8-nitro- (7CI, 9CI) (CA INDEX NAME)



L3 ANSWER 42 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1966:75774 CAPLUS
DOCUMENT NUMBER: 64:75774
ORIGINAL REFERENCE NO.: 64:14190b-g
TITLE: Intramolecular ring closure in N-propynylbarbituric acids and N-propynylbenzamides
AUTHOR(S): Schulte, K. E.; Reisch, J.; Sommer, M.
CORPORATE SOURCE: Westfaelischen Wilhelms-Univ., Muenster, Germany
SOURCE: Arch. Pharm. (1966), 299(2), 107-12
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 64:75774
GI For diagram(s), see printed CA Issue.
AB While condensation of CH2(CO2Et)2 (I) with H2NCONHCH2C.tplbond.CH (II) in the presence of Mg(OEt)2 forms N-propynylbarbituric acid (III), condensation of substituted malonic esters under the same condition leads to 7-substituted 2-methyloxazolino[3,2-c]uracils (IV). PhCONHCH2C.tplbond.CH (V) cyclizes only in the presence of concd. H2SO4 to give VI and by heating with P2S5 to give VII. (Hydrogenations were carried out in MeOH over Pd-CaCO3.) HC.tplbond.CCH2NH2.HCl (VIII.HCl) (12.4 g.) and 10.8 g. KCNO in 50 ml. H2O evapd. to dryness on a water bath, the

residue extd. with 100 ml. boiling abs. EtOH under reflux, and the ext. concd. in vacuo gave 9.9 g. II, m. 128-9.degree. (EtOH). Mg (2.43 g.) and a trace HgCl2 dissolved in 100 ml. abs. EtOH in a pressure flask, 13.2 g. I and 9.8 g. II added, and the soln. heated 8 hrs. at 110.degree. gave 11.2 g. III, m. 163-5.degree. (1:1 EtOH-H2O), which (332 mg.) on hydrogenation (89.1 ml. H absorbed) gave 1-propylbarbituric acid, m. 104.degree.. III (6.64 g.), 10.3 g. NaOAc, and 10.8 g. CH2:CHCH2Br dissolved in 50 ml. 1:1 EtOH-H2O by heating and the soln. refluxed 6 hrs. gave 5.6 g. 1-propynyl-5,5-diallylbarbituric acid, m. 106.degree. (H2O), which (246 mg.) absorbed 89.2 ml. H on hydrogenation. MeCH(CO2Et)2 (17.4 g.) treated with 9.8 g. II in the presence of Mg(OEt)2 (from 2.43 g. Mg) like III gave 3.4 g. IV (R = Me), m. 244-6.degree.. From 18.8 g. EtCH(CO2Et)2, 9.8 g. II, and Mg(OEt)2 (from 2.43 g. Mg) was similarly prepd. 8.1 g. IV (R = Et) (IX), m. 239-40.degree.. Similar treatment of 18.8 g. BuCH(CO2Et)2 or 23.7 g. PhCH(CO2Et)2 with 9.8 g. II and Mg(OEt)2 (from 2.43 g. Mg) gave 16.2 g. IV (R = Bu), m. 199-200.degree., and 7 g. IV (R = Ph), m. 320.degree., resp. IX (3.9 g.) dissolved in H2O with 2.24 g. KOH, 5.04 g. Me2SO4 in 20 ml. MeOH added dropwise, the soln. heated 6 hrs. on a water bath gave 0.8 g. 2,5-dimethyl-7-ethyloxazolino[3,2-c]uracil, m. 138.degree.. Hydantoin (5 g.) dissolved in MeOH with 2.8 g. KOH, 12.5 g. HC.tplbond.CCH2I added, and the soln. refluxed 6 hrs. gave 0.8 g. 3-propynylhydantoin (X), m. 186-7.degree., which (276 mg.) absorbed 90.3 ml. H on hydrogenation. X and 3-phenyl-5-propynylhydantoin underwent no reaction in the presence of concd. H2SO4 or H3PO4, the starting compds. always being recovered. From 14 g. BzCl, 9.1 g. VIII.HCl, and 8 g. NaOH in aq. soln. was obtained at room temp. 14 g. V, m. 118-19.degree. (1:1 C6H6-petroleum ether), which (318 mg.) absorbed 90 ml. H on hydrogenation. Ph2CHCOCl (19.3 g.), 1 g. VIII.HCl, and 8 g. NaOH in aq. soln. shaken at room temp. gave 18 g. Ph2CHCONHCH2C.tplbond.CH (XI), m. 108.degree. (1:1 C6H6-petroleum ether), which (424 mg.) absorbed 85.2 ml. H on hydrogenation. V (16 g.) and 50 ml. concd. H2SO4 heated in an oil bath 10 min. at 110.degree. gave 9 g. VI, b743 254-5.degree.. Similar treatment of 10.5 g. XI gave 2.6 g. Ph2CHCONHCH2COMe, m. 104.degree. (1:1 C6H6-petroleum ether). V (16.5 g.) and 40 g. P2S5 heated in an oil bath to 90.degree. and the mixt. worked up like VI gave 8 g. VII, b743 254-5.degree..

IT **5221-60-3**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,8-dimethyl- **5221-61-4**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-methyl-8-phenyl- **5221-63-6**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2,6-dimethyl- **5382-95-6**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-butyl-2-methyl- **5496-94-6**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2-methyl-
(prepn. of)

RN 5221-60-3 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 5,8-dimethyl- (8CI) (CA INDEX NAME)



RN 5221-61-4 CAPLUS

CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2-methyl-8-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 5221-63-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2,6-dimethyl- (7CI, 8CI) (CA INDEX NAME)



RN 5382-95-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-butyl-2-methyl- (7CI, 8CI) (CA INDEX NAME)



RN 5496-94-6 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 8-ethyl-2-methyl- (7CI, 8CI) (CA INDEX NAME)



L3 ANSWER 43 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1965:22582 CAPLUS
DOCUMENT NUMBER: 62:22582
ORIGINAL REFERENCE NO.: 62:4030b-d
TITLE: Carbon suboxide and some of its reactions. XIX. Reaction of carbon suboxide with 2-aminooxazoles,

10/ 071,032

-oxazine, and -thiazine
AUTHOR(S): Dashkevich, L. B.; Korbelainen, E. S.
CORPORATE SOURCE: Chem.-Pharm. Inst., Leningrad
SOURCE: Zhurnal Obshchei Khimii (1964), 34(10), 3427-9
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB cf. CA 61, 2965c. C3O2 passed into 2-aminobenzoxazole in Et2O gave 2,3-(dioxotetrahydropyrimido)benzoxazoline (I), m. 239-40.degree.. 2-Aminooxazole gave 2,3-(dioxotetrahydropyrimido)oxazoline, m. 226-7.degree.; 2-amino-5-phenyloxazole gave 2,3-(dioxo-tetrahydropyrimido)-5-phenyloxazoline, decompd. 281-2.degree.; 2-aminooxazoline gave 2,3-(dioxotetrahydropyrimido)oxazolidine, decompd. 130.degree.; 2-aminooxazine gave 2,3-(dioxotetrahydropyrimido)dihydrooxazine, m. 134-5.degree.; 2-aminothiazine gave 2,3-(dioxotetrahydropyrimido)dihydrothiazine (II), m. 200-2.degree.. The structure of the products was established by their ir spectra.
IT **40721-30-0**, 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro-
(prepn. of)
RN 40721-30-0 CAPLUS
CN 5H-Oxazolo[3,2-c]pyrimidine-5,7(6H)-dione, 2,3-dihydro- (9CI) (CA INDEX NAME)



L3 ANSWER 44 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1964:74894 CAPLUS
DOCUMENT NUMBER: 60:74894
ORIGINAL REFERENCE NO.: 60:13118g-h,13119a
TITLE: Aromaticity in heterocyclic systems. II. The application of n.m.r. in a study of the synthesis and structure of certain imidazo[1,2-c]pyrimidines and related pyrrolo[2,3-d]pyrimidines
AUTHOR(S): Noell, C. Wayne; Robins, Roland K.
CORPORATE SOURCE: Arizona State Univ., Tempe
SOURCE: Journal of Heterocyclic Chemistry (1964), 1(1), 34-41
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 60:74894
GI For diagram(s), see printed CA Issue.
AB cf. CA 59, 13966d. Nuclear magnetic resonance (n.m.r.) spectra were used to distinguish between ring closure to a deriv. of imidazo[1,2-c]pyrimidine or pyrrolo[2,3-d]pyrimidine. N.m.r. studies were also employed to select I as the most probable structure for 5-methylthio-2,7-dioxoimidazo[1,2-c]pyrimidine. Ultraviolet absorption spectra and n.m.r. studies in D2O support the conclusion that there is more aromaticity in the anion II than in the neutral mol. Several new synthetic routes to derivs. of imidazo[1,2-c]pyrimidine and pyrrolo[2,3-d]pyrimidine were described.
IT **90030-93-6**, Imidazo[1,2-c]pyrimidine-2,5,7(1H,3H,6H)-trione
(prepn. of)
RN 90030-93-6 CAPLUS

10/ 071,032

CN Imidazo[1,2-c]pyrimidine-2,5,7(1H,3H,6H)-trione (7CI) (CA INDEX NAME)



L3 ANSWER 45 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1962:404000 CAPLUS
DOCUMENT NUMBER: 57:4000
ORIGINAL REFERENCE NO.: 57:815f-i,816a-h
TITLE: Biosynthesis of pteridines. III. Synthesis of 1-deoxy1-pyrimidinylamino-2-ketoses
AUTHOR(S): Neilson, Thomas; Wood, H. C. S.
CORPORATE SOURCE: Roy. Coll. Sci. Technol., Glasgow, UK
SOURCE: Journal of the Chemical Society, Abstracts (1962) 44-5
CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. CA 55, 9413f. D-Glucosazone (20 g.), 100 cc. AcOH, 50 cc. EtOH, 20 cc. H2O and 5 g. PdO-BaSO4 hydrogenated overnight at 3-5 atm. gave 8 g. 1-amina-1-deoxy-D-fructose (I), m. 137.degree.. To 5 g. I acetate in 30 cc. EtOH was added 0.47 g. Na in 50 cc. EtOH, the whole kept 1 hr., and 2 g. 4-chloro-5-nitrouracil (Ia) in 50 cc. EtOH added to give 1-deoxy-1-(2,6-dihydroxy-5-nitro4-pyrimidinylamino)-D-fructose (II), as an extremely hygroscopic solid. II (335 mg.), 10 cc. H2O, and H2NOH (from 70 mg. H2NOH.HCl, 20 cc. EtOH, and 23 mg. Na) refluxed 1 hr. gave 250 mg. oxime, m. 291.degree., [.alpha.]D - 49.8.degree. (c 0.20, 0.05N NaOH). To 1.22. I in 10 cc. 1.2N NaOH was added 0.15g. NaBH4 in 10 cc. H2O with stirring, the whole kept 2 hrs., treated first with HCO2H, then with aq. NH3 to pH 9, and the whole chromatographed on Amberlite (G 400, HCO2- form), the column washed with HCO2NH4 buffers at pH 9 and 7 (0.13M in HCO2H), and the eluate concd. gave 0.8 g. 2,6-dihydroxy- 5 - nitro - 4 - D - sorbitylaminopyrimidine (III), needles, m. 225.degree., [.alpha.]D 15.degree. (c 0.18, 0.05N NaOH). The amino compd. (IV) from III and 3,4-dimethyl-o-benzoquinone gave 6,7-dimethyl-9-D-sorbitylisoalloxazine, m. 275.degree., [.alpha.]D -45.degree. (c 0.18, 0.05N NaOH). IV and alloxan in acid soln. gave 2,10-dihydro-4,6,8-trihydroxy-2-oxo-10- D-sorbitylpyrimido[5,4-g]pteridine. D-Arabinose (5 g.), 4 g. PhCH2NH2, and 50 cc. EtOH refluxed 0.25 hr. gave 5 g. glycosylamine (V), needles, m. 117-18.degree. (decompn.) (EtOH), [.alpha.]D -4.0.degree. (c 1.0, MeOH). To 5 g. V in 70 cc. dry dioxane was added 1.8 g. (CO2H)2 in 50 cc. dioxane and the whole warmed briefly to give 3 g. 1-benzylamino-1-deoxy-D-erythro-pentulose oxalate (VI), needles, m. 145-6.degree. (decompn.), [.alpha.]D 5.2.degree. (c 0.33, 0.05N NaOH). VI (2.8 g.) in 50 cc. EtOH and 1 g. Pd-C in 20 cc. EtOH hydrogenated until 1 mole H was absorbed gave 1 g. 1-amino-1-deoxy-D-erythro-pentulose oxalate (VII), m. 70.degree., [.alpha.]D -1.0.degree. (c 0.2, 0.05N NaOH). To 2.1 g. VII in 40 cc. EtOH and 10 cc. H2O was added 0.4 g. Na in 40 cc. EtOH, the whole filtered, 0.83 g. Ia in 30 cc. EtOH added to the filtrate, the whole heated 0.25 hr. on the steam bath, concd. in vacuo, and the residue treated with aq. NH3 to pH 10; chromatography as above gave 2,6dihydroxy-5-nitro-4-D-ribitylaminopyrimidine (VIII), as a jelly. VIII (.apprx.600 mg.) and 80 mg. NaBH4 as above gave 300 mg. 2,6-dihydroxy-5-nitro-4-D-ribitylaminopyrimidine (IX), noncryst. solid, m. 202.degree., [.alpha.]D 5.0.degree. (c 0.21, 0.05N NaOH). 5-Amino-4-D-ribitylaminouracil, from IX, gave riboflavine; IX also gave 2,10-dihydro-4,6,8-trihydroxy-2-oxo-10-D-

ribitylpyrimido[5,4-g]pteridine, yellow plates, m. 325.degree. (H2O), [.alpha.]D -33.degree. (c 0.2, 0.05N NaOH). To crude D-arabitylamine (from the Pt-catalyzed hydrogenation of 2 g. n-arabinose oxime) was added 1.15 g. Ia in 50 cc. EtOH, the whole kept 24 hrs. at room temp., filtered, the filtrate concd. in vacuo, and the residue dild. with 100 cc. EtOH gave 1.5 g. 4-D-arabitylamino-2,6-dihydroxy-5-nitropyrimidine, m. 185.degree. (aq. EtOH), [.alpha.]D -17.5.degree. (c 0.022, 0.05N NaOH), .lambda. 228, 322 m.mu. (.epsilon. 19,000, 10,900) at pH 1 and .lambda. 220, 335 m.mu. (.epsilon. 12,100, 13,400) at pH 13. 5-Amino-4-D-arabitylaminouracil (X) and the dimer of 3,4-dimethyl-o-benzoquinone gave 29% 9-D-arabityl-6,7-dimethylisoalloxazine, orange needles, m. 307-8.degree., [.alpha.]D 65.degree. (c 0.09, 0.05N NaOH); X and alloxan gave 67% 10-D-arabityl-2,10-dihydro-4,6,8trihydroxy-2-oxopyrimido [5,4-g]pteridine, m. above 325.degree. (N HCl), [.alpha.]D -76.degree. (c 0.20, 0.05N NaOH). 1-Deoxy-1-(2,6dihydroxy-5-nitro-4-pyrimidinylamino)-D-fructose (1 g.), 10 cc. H2O, and 0.5 g. Raney Ni hydrogenated 12 hrs., 2 cc. 2N NaOH added, the whole filtered, and the filtrate cooled gave 0.4 g. unstable Na salt of 7,8-dihydro-2,4-dihydroxy6-(D-arabo-tetrahydroxybutyl)pteridine (XI); XI dissolved in 2N NaOH and treated 3 days with a stream of O gave on acidification 2,4,6-trihydroxypteridine, yellow needles, m. 360-80.degree. (decompn.). H2NCMe(:NNHCONH2).HCl (4.62 g.), 0.64 g. Na in 40 cc. EtOH, and 2.66 g. Ia gave 4.0 g. 4-acetonylamino- 2,6- dihydroxy-5-nitropyrimidine semi-carbazone (XII), pale yellow needles, m. above 300.degree. (H2O); 1 g. XII and 50 cc. N HCl kept 3 days at 37.degree. gave 76% 4-acetonylamino-2,6-dihydroxy-5-nitropyrimidine (XIII), prisms, m. 273.degree. (H2O); 400 mg. XIII and 0.15 cc. H2NNH2.H2O in 60 cc. EtOH heated on the steam bath gave 83% hydrazone hydrazine salt (XIV), needles, m. above 300.degree. (H2O); 300 mg. XIII, 0.5 g. Raney Ni, and 25 cc. H2O hydrogenated overnight and worked up as above gave 67% 7,8-dihydropteridine (XV), pale yellow needles, m. above 300.degree., .lambda. 228, 267, 350 m.mu. (.epsilon. 11,200, 15,400, 4500) at pH 1, 226, 276, 318 m.mu. (.epsilon. 2300, 13,000, 6500) at pH 13. XV (120 mg.), 25 cc. 0.1N NaOH, and 2.2 cc. 0.2M KMnO4 kept 2-3 min., the whole filtered, and the filtrate acidified gave 67% 2,4-dihydroxy6-methylpteridine (XVI), needles, m. above 300.degree.. XIV (200 mg.), 25 cc. H2O, and 0.5 g. Raney Ni hydrogenated 24 hrs. gave XVI. XII (2 g.) and 50 cc. 2N HCl refluxed 0.25 hr. gave 1.2 g. 4,5-dihydro-7-hydroxy-3-methyl-8-nitro-5-oxoimidazo[1,2-c]pyrimidine, needles, m. 265.degree. (H2O), .lambda. 224, 268, 360 m.mu. (.epsilon. 10,600, 5500, 11,600) at pH 1, .lambda. 238, 394 (.epsilon. 12,000, 9700) at pH 13. 4-(2-Hydroxyethylamino)5-nitrouracil (2 g.) and 200 cc. N HCl refluxed 0.25 hr. gave 1.4 g. 1,2,3,5-tetrahydro-7-hydroxy-8-nitro-5-oxoimidazo[1,2-c]pyrimidine, needles, m. 275.degree., .lambda. 228, 322 m.mu. (.epsilon. 24,000, 13,500) at pH 1, .lambda. 221, 334 m.mu. (.epsilon. 15,800, 16,400) at pH 13.

IT **77178-47-3**, Imidazo[1,2-c]pyrimidin-5(1H)-one, 2,3-dihydro-7-hydroxy-8-nitro- **91808-86-5**, Imidazo[1,2-c]pyrimidin-5(1H)-one, 7-hydroxy-3-methyl-8-nitro-
(prepn. of)

RN 77178-47-3 CAPLUS

CN Imidazo[1,2-c]pyrimidine-5,7(1H,6H)-dione, 2,3-dihydro-8-nitro- (9CI) (CA INDEX NAME)



10/ 071,032

RN 91808-86-5 CAPLUS
CN Imidazo[1,2-c]pyrimidin-5(1H)-one, 7-hydroxy-3-methyl-8-nitro- (7CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 13:27:29 ON 14 JAN 2004)

FILE 'REGISTRY' ENTERED AT 13:28:14 ON 14 JAN 2004
L1 STRUCTURE UPLOADED
L2 593 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:29:20 ON 14 JAN 2004
L3 45 S L2

=> log y